country_alpha_3_code,country,partner_management,partner_management_justification,hbv_screening_for_hbsag,hbv_screening_for_hbsag_justification,vaccination_for_hbv,vaccination_for_hbv_justification,vaccination_for_hpv,vaccination_for_hpv_justification,syphilis_screening,syphilis_screening_justification,ng_screening,ng_screening_justification,ct_screening,ct_screening_justification
ALB,Albania,ERR: yes (REF: no),"ALB HIV Guidelines ENG.pdf: Page 58, 'Counselling' section, last point: 'Assess intimate partner violence and gender based violence.'",yes,"ALB HIV Guidelines ENG.pdf: Page 54, 'Initial contact management' section: 'Look for basic creatinine, hematology, liver function, HCV, antiHBs and HBsAg and EIA for HIV.'; Page 57, 'Table 35: Summarization of Initial Assessment and Follow-up Following', 'HBsAg' row: 'At the beginning. If you vaccinate negatively. If positive, refer to your hepatologist and advise against stopping PrEP due to the risk of inflaming hepatitis.'",yes,"ALB HIV Guidelines ENG.pdf: Page 57, 'Table 35: Summarization of Initial Assessment and Follow-up Following', 'Review vaccinations' row: 'First (focus on HBV, HPV, HAV, DT)'",yes,"ALB HIV Guidelines ENG.pdf: Page 57, 'Table 35: Summarization of Initial Assessment and Follow-up Following', 'Review vaccinations' row: 'First (focus on HBV, HPV, HAV, DT)'",yes,"ALB HIV Guidelines ENG.pdf: Page 57, 'Table 35: Summarization of Initial Assessment and Follow-up Following', 'VDRL or RPR' row: 'First, and repeat every six months.'",yes,"ALB HIV Guidelines ENG.pdf: Page 57, 'Table 35: Summarization of Initial Assessment and Follow-up Following', 'CT/NG' row: 'Depending on availability, at the beginning and every 6 months (rectal PCR, tampon and urine).'",yes,"ALB HIV Guidelines ENG.pdf: Page 57, 'Table 35: Summarization of Initial Assessment and Follow-up Following', 'CT/NG' row: 'Depending on availability, at the beginning and every 6 months (rectal PCR, tampon and urine).'"
AND,Andorra,no,Justification not provided,yes,"AND PrEP Guidelines ENG.pdf: Page 6, 'Analytical determination' -> 'Sexually transmitted infections (STIs) screenings (see Table 1):' -> 'Hepatitis B (HBV)'; Page 7, Table 1 -> 'HBV' -> 'Anti HBs*, anti HBc and HBsAg serology'",yes,"AND PrEP Guidelines ENG.pdf: Page 5, 'Personal assessment of the candidate (clinical interview)' -> 'Vaccination against hepatitis A virus (HBV) and hepatitis B (HBV)'",yes,"AND PrEP Guidelines ENG.pdf: Page 5, 'Personal assessment of the candidate (clinical interview)' -> 'Vaccination ... and against human papillomavirus (HPV)'; Page 8, paragraph 1, 'HPV vaccination in MSM (men who have sex with other men) under the age of 26 is recommended'",yes,"AND PrEP Guidelines ENG.pdf: Page 6, 'Analytical determination' -> 'Sexually transmitted infections (STIs) screenings (see Table 1):' -> 'Syphilis'; Page 7, Table 1 -> 'Treponema pallidum'",yes,"AND PrEP Guidelines ENG.pdf: Page 6, 'Analytical determination' -> 'Sexually transmitted infections (STIs) screenings (see Table 1):' -> 'Gonorrhea'; Page 7, Table 1 -> 'Neisseria gonorrhoeae'",yes,"AND PrEP Guidelines ENG.pdf: Page 6, 'Analytical determination' -> 'Sexually transmitted infections (STIs) screenings (see Table 1):' -> 'Chlamydia'; Page 7, Table 1 -> 'Clamydia trachomatis'"
ARG,Argentina,yes,"Argentina PrEP Guía de directrices clínicas_Final.pdf: Page 20, paragraph under 'Sífilis': 'En caso de confirmarse infección por sífilis, se recomienda el tratamiento inmediato a la persona y su/s pareja/s de acuerdo a los algoritmos vigentes'. Page 20, paragraph under 'Gonorrea y clamidia': 'Debe realizarse el tratamiento precoz de las personas en quienes se detecte infección por clamidia y gonococo y su/s pareja/s'.",yes,"Argentina PrEP Guía de directrices clínicas_Final.pdf: Page 14, section 'Diagnóstico y tratamiento inicial de ITS': 'HBV en individuos no vacunados (incluyendo detección de... antígeno de superficie [HBsAg])'. Page 17, Table 6, row 'Test de hepatitis B': 'HBsAg (solo en individuos no vacunados)' is recommended at 'Basal', 'Al mes', and 'Trimestral'.",yes,"Argentina PrEP Guía de directrices clínicas_Final.pdf: Page 9, section '1.8. Inmunizaciones': 'Además de la vacunación contra la hepatitis B (HBV)... en las personas candidatas a recibir PrEP'. Page 14, section 'Inmunizaciones': 'Todas las personas que sean candidatas a PrEP... deben recibir inmunización contra HBV'.",yes,"Argentina PrEP Guía de directrices clínicas_Final.pdf: Page 9, section '1.8. Inmunizaciones': 'Es recomendable además la vacunación contra el virus del papiloma humano (VPH) en personas menores de 26 años que accedan a servicios de Prevención combinada'. Page 14, section 'Inmunizaciones': 'En personas menores de 26 años, debe considerarse la indicación de inmunización contra el VPH siguiendo las recomendaciones vigentes'.",yes,"Argentina PrEP Guía de directrices clínicas_Final.pdf: Page 12, Table 3, section 'Indispensable': 'Testeo y tratamiento de sífilis'. Page 14, section 'Diagnóstico y tratamiento inicial de ITS': 'Se recomienda en todos los casos el screening de sífilis'. Page 17, Table 6, row 'Test de sífilis.': Recommended at 'Basal' and 'Trimestral'.",yes,"Argentina PrEP Guía de directrices clínicas_Final.pdf: Page 12, Table 3, section 'Indispensable': 'Testeo y tratamiento de... gonorrea'. Page 14, section 'Diagnóstico y tratamiento inicial de ITS': 'se recomienda el screening de clamidia y gonorrea... a través de la realización de pruebas moleculares'. Page 17, Table 6, row 'Búsqueda de chlamydia y gonococo': Recommended at 'Basal' and 'Trimestral'.",yes,"Argentina PrEP Guía de directrices clínicas_Final.pdf: Page 12, Table 3, section 'Indispensable': 'Testeo y tratamiento de... chlamydia'. Page 14, section 'Diagnóstico y tratamiento inicial de ITS': 'se recomienda el screening de clamidia y gonorrea... a través de la realización de pruebas moleculares'. Page 17, Table 6, row 'Búsqueda de chlamydia y gonococo': Recommended at 'Basal' and 'Trimestral'."
ARM,Armenia,no,ARM PrEP Guidelines ENG.pdf: The document mentions identifying high-risk partners for PrEP eligibility but does not explicitly recommend partner testing or treatment for other STIs (excluding HIV).,yes,"ARM PrEP Guidelines ENG.pdf: Page 3, Section 9, point 3: 'clarify the status of hepatitis B if HBsAg is positive should be guided by the hepatitis B driving guide...'; Page 13, Table 'Hepatitis B (HBsAg)' listed under 'Tess' (Tests).",yes,"ARM PrEP Guidelines ENG.pdf: Page 3, Section 9, point 3: '...if HBsAg is negative, it is recommended to test and vaccinate anti-HBc'; Page 13, Table 'Hepatitis B (HBsAg)' row, 'Additional steps' column has 'Vaccinated If Negative'.",no,Justification not provided,yes,"ARM PrEP Guidelines ENG.pdf: Page 4, Section 9, point 5: 'it is desirable to perform other sexually transmitted infections (syphilis, chlamydia) infections, Gonococcus infection, hepatitis C (HIV))'.",yes,"ARM PrEP Guidelines ENG.pdf: Page 4, Section 9, point 5: 'it is desirable to perform other sexually transmitted infections...Gonococcus infection...'",yes,"ARM PrEP Guidelines ENG.pdf: Page 4, Section 9, point 5: 'it is desirable to perform other sexually transmitted infections (syphilis, chlamydia) infections...'"
AUS,Australia,yes,"PrEP-guidelines-sep-2019.pdf: Page 46, 'Testing for STIs' section, paragraph 1: 'Partner notification should be undertaken using the most appropriate available resources.'",yes,"PrEP-guidelines-sep-2019.pdf: Page 27, 'Assessment of hepatitis A, B and C status' section, paragraph 1: 'Hepatitis A, HBV and HCV infection status should be documented by screening serology when PrEP is initiated.' Page 43, Table 7.1: 'Hepatitis B serology' is recommended at 'Baseline (Week 0)'. Page 54, 'Patients with chronic active HBV infection' section, paragraph 3: 'All people who test positive for hepatitis B surface antigen (HBsAg) should be evaluated by a clinician experienced in the treatment of HBV infection.'",yes,"PrEP-guidelines-sep-2019.pdf: Page 27, 'Assessment of hepatitis A, B and C status' section, paragraph 2: 'Vaccination against hepatitis A and HBV is recommended for all susceptible priority populations, which include MSM, sex workers, people from countries with a high HIV, HBV or HCV prevalence, and their sexual partners and people who inject drugs (27, 28). Individuals identified at baseline as having undiagnosed chronic hepatitis B should be referred to a clinician experienced in the management of hepatitis B for treatment assessment.' Page 43, Table 7.1: 'Vaccinate if non-immune' for Hepatitis B serology at 'Baseline (Week 0)'.",no,Justification not provided,yes,"PrEP-guidelines-sep-2019.pdf: Page 23, 'Assessment and management of sexually transmissible infections at baseline' section, paragraph 1: 'Clinicians should screen for STIs (specifically gonorrhoea, chlamydia and infectious syphilis) using the standard-of-care tests and procedures'. Page 43, Table 7.1: 'STI (i.e. syphilis, gonorrhoea, chlamydia) as per Australian STI Management Guidelines' is recommended at 'Baseline (Week 0)' and 'Every subsequent 90 days on PrEP'. Page 44, Box 7.1: 'Test for sexually transmissible infections (STIs). This involves PCR tests for chlamydia (first-pass urine, pharyngeal swab and anal swab) and Neisseria gonorrhoea, (pharyngeal swab and anal swab) and a blood test for syphilis serology' 'At least every 3 months'.",yes,"PrEP-guidelines-sep-2019.pdf: Page 23, 'Assessment and management of sexually transmissible infections at baseline' section, paragraph 1: 'Clinicians should screen for STIs (specifically gonorrhoea, chlamydia and infectious syphilis) using the standard-of-care tests and procedures'. Page 43, Table 7.1: 'STI (i.e. syphilis, gonorrhoea, chlamydia) as per Australian STI Management Guidelines' is recommended at 'Baseline (Week 0)' and 'Every subsequent 90 days on PrEP'. Page 44, Box 7.1: 'Test for sexually transmissible infections (STIs). This involves PCR tests for chlamydia (first-pass urine, pharyngeal swab and anal swab) and Neisseria gonorrhoea, (pharyngeal swab and anal swab) and a blood test for syphilis serology' 'At least every 3 months'.",yes,"PrEP-guidelines-sep-2019.pdf: Page 23, 'Assessment and management of sexually transmissible infections at baseline' section, paragraph 1: 'Clinicians should screen for STIs (specifically gonorrhoea, chlamydia and infectious syphilis) using the standard-of-care tests and procedures'. Page 43, Table 7.1: 'STI (i.e. syphilis, gonorrhoea, chlamydia) as per Australian STI Management Guidelines' is recommended at 'Baseline (Week 0)' and 'Every subsequent 90 days on PrEP'. Page 44, Box 7.1: 'Test for sexually transmissible infections (STIs). This involves PCR tests for chlamydia (first-pass urine, pharyngeal swab and anal swab) and Neisseria gonorrhoea, (pharyngeal swab and anal swab) and a blood test for syphilis serology' 'At least every 3 months'."
AUT,Austria,yes,"Austria -Germany Leitlinien zur PrEP_Stand 2018.pdf: Page 26, 'Abstimmung des Leitlinien-Gesamttexts' section, last sentence: 'Eine Partner*innen-Mitbehandlung wird empfohlen.'",yes,"Austria -Germany Leitlinien zur PrEP_Stand 2018.pdf: Page 15, Empfehlung 1.6, third bullet point: 'Ausschluss einer replikativen Hepatitis-B-Infektion mittels Serologie (HBs-Antigen, anti-HBc-Antikörper)'; Page 19, Table 2.1, row 'Hepatitis B*': 'X' for 'VOR PrEP Beginn', and '*=antiHBsAk, HBsAg, antiHBcAk'.",yes,"Austria -Germany Leitlinien zur PrEP_Stand 2018.pdf: Page 15, Empfehlung 1.6, third bullet point: 'Prüfung der HBV-Immunität (HBs-Antikörper, ggfs. Impfung gegen HBV)'; Page 16, Kommentar for Empfehlung 1.7, second paragraph: 'Die Prüfung der HBV-Immunität bei Abwesenheit einer Infektion sollte Anlass zur Überprüfung des gesamten Impfstatus und ggfs. der Komplettierung des Impfschutzes auch bezüglich HAV bei MSM sein, insbesondere aufgrund von bekannten Ausbruchssituationen in Europa [17,18].'",no,Justification not provided,yes,"Austria -Germany Leitlinien zur PrEP_Stand 2018.pdf: Page 19, Table 2.1, row 'Lues-Serologie': 'X' for 'VOR PrEP Beginn' and 'Alle 3 Monate' for 'Während PrEP'; Page 21, Kommentar for Empfehlung 2.1, third paragraph: 'Dazu werden regelmäßige 3-monatliche serologische Untersuchungen auf Syphilis... empfohlen.'",yes,"Austria -Germany Leitlinien zur PrEP_Stand 2018.pdf: Page 19, Table 2.1, row 'Gonorrhoe-NAAT**': 'X' for 'VOR PrEP Beginn' and 'Alle 3-6 Monate' for 'Während PrEP', with '**pharyngeal, anorektal, genital'; Page 21, Kommentar for Empfehlung 2.1, third paragraph: 'Abstrichuntersuchungen bei asymptomatischen PrEP-Nutzer*innen auf Chlamydia trachomatis und Neisseria gonorrhoeae (pharyngeal, genital und anorektal; ggfs. pooling möglich) werden alle 3-6 Monate empfohlen.'",yes,"Austria -Germany Leitlinien zur PrEP_Stand 2018.pdf: Page 19, Table 2.1, row 'Chlamydien-NAAT**': 'X' for 'VOR PrEP Beginn' and 'Alle 3-6 Monate' for 'Während PrEP', with '**pharyngeal, anorektal, genital'; Page 21, Kommentar for Empfehlung 2.1, third paragraph: 'Abstrichuntersuchungen bei asymptomatischen PrEP-Nutzer*innen auf Chlamydia trachomatis und Neisseria gonorrhoeae (pharyngeal, genital und anorektal; ggfs. pooling möglich) werden alle 3-6 Monate empfohlen.'"
BHS,The Bahamas,no,"HIV PrEP GuidelinesSOP Bahamas.pdf: While 'intimate partner violence' is mentioned under Counselling (Page 4), it is not specified in the context of one partner having an STI (excluding HIV).",yes,"HIV PrEP GuidelinesSOP Bahamas.pdf: Baseline Hepatitis B screening (Page 2, Section 2.2) and Hepatitis B surface antigen (Table 1, Page 3)",yes,"HIV PrEP GuidelinesSOP Bahamas.pdf: If negative, consider vaccination against hepatitis B (Table 1, Page 3)",no,HIV PrEP GuidelinesSOP Bahamas.pdf: Not mentioned,yes,"HIV PrEP GuidelinesSOP Bahamas.pdf: Rapid plasma reagin (RPR) (Table 1, Page 3)",no,HIV PrEP GuidelinesSOP Bahamas.pdf: Only general STI screening is mentioned without specific pathogen for Neisseria gonorrhoeae,no,HIV PrEP GuidelinesSOP Bahamas.pdf: Only general STI screening is mentioned without specific pathogen for Chlamydia trachomatis
BRB,Barbados,yes,"Guidelines for PrEP for HIV Prevention in Barbados - Nov. 20, 2017.pdf: Page 15, Annex 3, 'Counselling' section, 'To assess intimate partner violence and gender-based violence.'",yes,"Guidelines for PrEP for HIV Prevention in Barbados - Nov. 20, 2017.pdf: Page 7, 'Key elements of PrEP services', point 6: 'Testing PrEP users for HBV surface antigen is desirable'; Page 15, Annex 3, 'Hepatitis B surface antigen' row",yes,"Guidelines for PrEP for HIV Prevention in Barbados - Nov. 20, 2017.pdf: Page 7, 'Key elements of PrEP services', point 6: 'HBV vaccination for those who are uninfected'; Page 15, Annex 3, 'Hepatitis B surface antigen' row, 'If negative, consider vaccination against hepatitis B.'",yes,"Guidelines for PrEP for HIV Prevention in Barbados - Nov. 20, 2017.pdf: Page 15, Annex 3, 'Review vaccination history' row, 'consider vaccination for human papilloma virus.'",yes,"Guidelines for PrEP for HIV Prevention in Barbados - Nov. 20, 2017.pdf: Page 15, Annex 3, 'Screening for Sexually Transmitted Infection (STIs)' row, 'To diagnose and treat STIs (Syphilis, Chlamydia and Gonorrhea)'; Page 16, Annex 4, 'At least every 12 months to', 'Conduct STI testing (syphilis, gonorrhea, chlamydia)'",yes,"Guidelines for PrEP for HIV Prevention in Barbados - Nov. 20, 2017.pdf: Page 15, Annex 3, 'Screening for Sexually Transmitted Infection (STIs)' row, 'To diagnose and treat STIs (Syphilis, Chlamydia and Gonorrhea)'; Page 16, Annex 4, 'At least every 12 months to', 'Conduct STI testing (syphilis, gonorrhea, chlamydia)'",yes,"Guidelines for PrEP for HIV Prevention in Barbados - Nov. 20, 2017.pdf: Page 15, Annex 3, 'Screening for Sexually Transmitted Infection (STIs)' row, 'To diagnose and treat STIs (Syphilis, Chlamydia and Gonorrhea)'; Page 16, Annex 4, 'At least every 12 months to', 'Conduct STI testing (syphilis, gonorrhea, chlamydia)'"
BLR,Belarus,no,"BLR HIV Guidelines ENG.pdf: The document identifies 'sexual partners of PLHIV who have not achieved viral suppression' as a high-risk group for PrEP (Page 16, Section 67), and mentions 'a new episode of sexually transmitted infection' as an indication for PrEP (Page 16, Section 74), but does not explicitly recommend partner management (testing, treatment, or contact tracing) in the context of STIs for PrEP users. Page 18, Section 82, advises the PrEP user to seek further medical examination for STIs and avoid unprotected sex, but does not specify partner management.",yes,"BLR HIV Guidelines ENG.pdf: Page 17, Section 75 states: 'Before prescribing PrEP, the following diagnostic measures are carried out: ... determination of HBsAg. A positive determination result is not a medical contraindication to PrEP, but requires additional medical examination to decide on the need for antiviral therapy for HBV infection'.",no,"BLR HIV Guidelines ENG.pdf: Page 26, Annex 5, item 15, mentions 'HBV vaccination is offered to seronegative people' within a general monitoring algorithm for HIV infection, but it is not explicitly stated as a recommendation for PrEP users at initiation or during PrEP use within the PrEP-specific chapter (Chapter 9) or sections dedicated to PrEP guidelines.",no,BLR HIV Guidelines ENG.pdf: No mention of Human Papillomavirus (HPV) vaccination recommendations for PrEP users.,ERR: yes (REF: no),"BLR HIV Guidelines ENG.pdf: Page 16, Section 74 states 'Determination of medical indications for the use of PrEP is carried out by interviewing on the basis of the presence of any of the factors at high risk of HIV infection over the past 6 months: ... a new episode of sexually transmitted infection (hereinafter referred to as STIs) (syphilis, gonorrhea, chlamydia)'. This implies screening for syphilis to determine PrEP indication. Page 18, Section 80, also notes 'examination for STIs' during PrEP monitoring.",ERR: yes (REF: no),"BLR HIV Guidelines ENG.pdf: Page 16, Section 74 states 'Determination of medical indications for the use of PrEP is carried out by interviewing on the basis of the presence of any of the factors at high risk of HIV infection over the past 6 months: ... a new episode of sexually transmitted infection (hereinafter referred to as STIs) (syphilis, gonorrhea, chlamydia)'. This implies screening for gonorrhea to determine PrEP indication. Page 18, Section 80, also notes 'examination for STIs' during PrEP monitoring.",ERR: yes (REF: no),"BLR HIV Guidelines ENG.pdf: Page 16, Section 74 states 'Determination of medical indications for the use of PrEP is carried out by interviewing on the basis of the presence of any of the factors at high risk of HIV infection over the past 6 months: ... a new episode of sexually transmitted infection (hereinafter referred to as STIs) (syphilis, gonorrhea, chlamydia)'. This implies screening for chlamydia to determine PrEP indication. Page 18, Section 80, also notes 'examination for STIs' during PrEP monitoring."
BEL,Belgium,no,Justification not provided,yes,"Belgian PrEP guidelines.pdf: Page 7, table, row 'HBV/HAV screening and immunization', column 'Before PrEP'; Page 8, table, row 'Hepatitis A/B screening and immunization' lists 'AgHBs, AcHBs, AcHBc, IgG HBA'.",yes,"Belgian PrEP guidelines.pdf: Page 7, table, row 'HBV/HAV screening and immunization'; Page 8, table, row 'Hepatitis A/B screening and immunization' explicitly includes 'immunization'.",no,Justification not provided,yes,"Belgian PrEP guidelines.pdf: Page 7, table, row 'Syphilis screening', column 'Before PrEP' and '3months later'; Page 8, table, row 'Syphilis screening' lists 'Screening +/- VDRL +/- TPHA'.",yes,"Belgian PrEP guidelines.pdf: Page 7, table, row 'Gonocoque and Chlamydia screening', column 'Before PrEP' and '3months later'; Page 8, table, row 'Screening gonocoque/chlamydia' lists 'PCR (throat, anus and first pass urine)'.",yes,"Belgian PrEP guidelines.pdf: Page 7, table, row 'Gonocoque and Chlamydia screening', column 'Before PrEP' and '3months later'; Page 8, table, row 'Screening gonocoque/chlamydia' lists 'PCR (throat, anus and first pass urine)'."
BEN,Benin,no,"Bening_ENG_GUIDE NATIONAL DE MISE EN ŒUVRE DE LA PROPHYLAXIE PRE EXPOSITION FINAL (1) copy.pdf: The document mentions managing STIs according to standard guidelines (Page 29, Table II) and using a syndromic management algorithm for STIs (Page 31), which may imply partner management, but it does not explicitly state 'partner(s) testing', 'partner(s) treatment', 'partner(s) management', 'partner services', or 'contact tracing' in the context of one partner having an STI (excluding HIV).",yes,"Bening_ENG_GUIDE NATIONAL DE MISE EN ŒUVRE DE LA PROPHYLAXIE PRE EXPOSITION FINAL (1) copy.pdf: Page 28, Table II: 'To research Hepatitis of Surface Antigen'; Page 29, Table II: 'If the HBsAg result is positive, the client can be initiated on continuous PrEP'.",yes,"Bening_ENG_GUIDE NATIONAL DE MISE EN ŒUVRE DE LA PROPHYLAXIE PRE EXPOSITION FINAL (1) copy.pdf: Page 28, Table II: 'HBsAg negative: Explore and offer hepatitis B vaccination (in accordance with national hepatitis guidelines)'; Page 31: 'Vaccinations may also be offered (hepatitis B)'.",no,Justification not provided,yes,"Bening_ENG_GUIDE NATIONAL DE MISE EN ŒUVRE DE LA PROPHYLAXIE PRE EXPOSITION FINAL (1) copy.pdf: Page 14: 'PrEP... does not protect against other STIs... such as... syphilis... it is therefore essential to have regular check-ups for STIs'; Page 18: 'Syphilis or other bacterial, viral or parasitic anal STI, particularly if This was diagnosed within the last six months'; Page 31: 'Regularly check up on STIs: PrEP does not prevent other STIs (gonorrhea, condyloma, chlamydia, hepatitis B/C, syphilis, etc.)'.",yes,"Bening_ENG_GUIDE NATIONAL DE MISE EN ŒUVRE DE LA PROPHYLAXIE PRE EXPOSITION FINAL (1) copy.pdf: Page 14: 'PrEP... does not protect against other STIs... such as gonorrhea... it is therefore essential to have regular check-ups for STIs'; Page 31: 'Regularly check up on STIs: PrEP does not prevent other STIs (gonorrhea, condyloma, chlamydia, hepatitis B/C, syphilis, etc.)'.",yes,"Bening_ENG_GUIDE NATIONAL DE MISE EN ŒUVRE DE LA PROPHYLAXIE PRE EXPOSITION FINAL (1) copy.pdf: Page 14: 'PrEP... does not protect against other STIs... such as... chlamydia... it is therefore essential to have regular check-ups for STIs'; Page 31: 'Regularly check up on STIs: PrEP does not prevent other STIs (gonorrhea, condyloma, chlamydia, hepatitis B/C, syphilis, etc.)'."
BIH,Bosnia and Herzegovina,no,BiH HIV Guidelines ENG.pdf: Not found within the PrEP guidelines. Mentions 'joint HIV testing with partners' on Page 68 but not STI specific partner management.,yes,"BiH HIV Guidelines ENG.pdf: Page 65, under '2.18.1. Indications and recommendations for PrEP', 'Basic laboratory testing', 'Testing for hepatitis B'.",no,"BiH HIV Guidelines ENG.pdf: Not found in the context of PrEP initiation or follow-up. HBV testing is mentioned, but not vaccination for PrEP users.",no,BiH HIV Guidelines ENG.pdf: Not found in the context of PrEP initiation or follow-up.,yes,"BiH HIV Guidelines ENG.pdf: Page 65, under '2.18.1. Indications and recommendations for PrEP', 'Basic laboratory testing', 'Serological testing for sexually transmitted diseases: syphilis'.",yes,"BiH HIV Guidelines ENG.pdf: Page 65, under '2.18.1. Indications and recommendations for PrEP', 'Basic laboratory testing', 'Serological testing for sexually transmitted diseases: ... gonorrhea'.",yes,"BiH HIV Guidelines ENG.pdf: Page 65, under '2.18.1. Indications and recommendations for PrEP', 'Basic laboratory testing', 'Serological testing for sexually transmitted diseases: ... chlamydia'."
BWA,Botswana,no,"Botswana Handbook_HIV_treatment_guidelines.pdf: The document mentions PrEP for discordant couples (Page 7, 8) but does not specify partner management, contact tracing, or partner testing/treatment for STIs (excluding HIV) within the PrEP context.",no,Botswana Handbook_HIV_treatment_guidelines.pdf: Not found within the context of PrEP services or PrEP users.,no,Botswana Handbook_HIV_treatment_guidelines.pdf: Not found within the context of PrEP services or PrEP users.,no,Botswana Handbook_HIV_treatment_guidelines.pdf: Not found within the context of PrEP services or PrEP users.,no,Botswana Handbook_HIV_treatment_guidelines.pdf: Not found within the context of PrEP services or PrEP users.,no,Botswana Handbook_HIV_treatment_guidelines.pdf: Not found within the context of PrEP services or PrEP users.,no,Botswana Handbook_HIV_treatment_guidelines.pdf: Not found within the context of PrEP services or PrEP users.
BRA,Brazil,no,"protocolo_clinico_profilaxia_prep.pdf: The document mentions partner testing for HIV (Page 41, Section 6, first paragraph) but does not specify partner management (testing, treatment, or contact tracing) for other STIs (excluding HIV) in the context of a PrEP user having an STI.",yes,"protocolo_clinico_profilaxia_prep.pdf: Page 19, section 2.6, third paragraph: 'O perfil sorológico para as hepatites virais B (HBsAg, anti-HBs e anti-HBc – total e IgM) e C (anti-HCV) deve ser documentado em todas as pessoas com indicação de PrEP, com exames solicitados e coletados na consulta inicial.'; Page 37, Quadro 3, row 'Teste para hepatite B(b)'.",yes,"protocolo_clinico_profilaxia_prep.pdf: Page 20, first paragraph under 2.6: 'A vacinação contra a hepatite B é recomendada para todas as pessoas, em qualquer faixa etária. Os segmentos populacionais com indicação de PrEP também são prioritários para receber o esquema vacinal completo (geralmente de três doses).'",no,"protocolo_clinico_profilaxia_prep.pdf: While 'Imunizar para HBV e HPV' is present in Figure 2 on Page 28 as part of combined prevention, there is no specific textual recommendation for HPV vaccination explicitly for PrEP users or at the initiation of PrEP services.",yes,"protocolo_clinico_profilaxia_prep.pdf: Page 19, section 2.5, second paragraph: 'Assim, recomenda-se realizar a testagem para sífilis, preferencialmente por teste rápido, instituindo-se o tratamento quando indicado.'; Page 37, Quadro 3, row 'Teste para sífilis'.",yes,"protocolo_clinico_profilaxia_prep.pdf: Page 19, section 2.5, second paragraph: 'Indica-se, também, pesquisa para Chlamydia sp. e gonococo, quando disponível, e tratamento, quando indicado.'; Page 37, Quadro 3, row 'Identificação de outras IST (clamídia e gonococo)'.",yes,"protocolo_clinico_profilaxia_prep.pdf: Page 19, section 2.5, second paragraph: 'Indica-se, também, pesquisa para Chlamydia sp. e gonococo, quando disponível, e tratamento, quando indicado.'; Page 37, Quadro 3, row 'Identificação de outras IST (clamídia e gonococo)'."
BFA,Burkina Faso,no,"BF_Guide PrEP_Burkina Faso_vf2 (Récupération automatique).pdf: The document mentions referral for individuals with Hepatitis B (Page 17, section 6.1 and 6.2; Page 23, section 9.3) and general STI management (Page 17, section 6.1 and 6.2), but does not explicitly mention partner testing, treatment, management, or contact tracing for non-HIV STIs in the context of PrEP users' sexual partners.",yes,"BF_Guide PrEP_Burkina Faso_vf2 (Récupération automatique).pdf: Page 10, section 4: 'Les individus de sexe masculin infectés ou soupçonnés d'être par le virus de l'hépatite B (Ag HBS positif ou indéterminé) ne peuvent pas bénéficier de la PrEP à la demande.' and Page 20, Table 1: 'AgHBs' listed under 'Bilan biologique obligatoire' at 'J0 ou inclusion'.",yes,"BF_Guide PrEP_Burkina Faso_vf2 (Récupération automatique).pdf: Page 17, section 6.1 and 6.2: 'Vaccination contre l'hépatite B'; Page 20, Table 1: 'Vaccination contre l'hépatite B' with a schedule.",no,Justification not provided,yes,"BF_Guide PrEP_Burkina Faso_vf2 (Récupération automatique).pdf: Page 20, Table 1: 'Syphilis (TPHA+VDRL)' listed under 'Bilan biologique conseillé'.",yes,"BF_Guide PrEP_Burkina Faso_vf2 (Récupération automatique).pdf: Page 20, Table 1: 'PCR Chlamydiase, Gonococcie' listed under 'Bilan biologique conseillé'; Page 24, section 10.3: 'tests PCR pour la recherche d'IST à gonocoque'.",yes,"BF_Guide PrEP_Burkina Faso_vf2 (Récupération automatique).pdf: Page 20, Table 1: 'PCR Chlamydiase, Gonococcie' listed under 'Bilan biologique conseillé'; Page 24, section 10.3: 'tests PCR pour la recherche d'IST à ... chlamydia'."
BDI,Burundi,no,"Burundi 2020.10 PLAN DE MISE EN OEUVRE DES DIRECTIVES DE TARV 2020_VF PREFACEE_09 Oct 2020.fr.en.pdf: Partner management for STIs in the context of PrEP users is not explicitly mentioned. General 'treatment for STIs' is mentioned for the PrEP user, but not for partners.",ERR: yes (REF: no),"Burundi 2020.10 PLAN DE MISE EN OEUVRE DES DIRECTIVES DE TARV 2020_VF PREFACEE_09 Oct 2020.fr.en.pdf: Page 63, Appendix 1, 'Other recommended actions: Hepatitis B assessment'; Page 17, 'The client should be examined for possible contraindications and other pre-existing pathologies (renal pathologies, hepatitis B)' and 'If HIV / Hepatitis B co-infection at the start of PrEP, continue the TDF / 3TC and adapt the ARV treatment according to the national protocol.'",ERR: yes (REF: no),"Burundi 2020.10 PLAN DE MISE EN OEUVRE DES DIRECTIVES DE TARV 2020_VF PREFACEE_09 Oct 2020.fr.en.pdf: Page 63, Appendix 1, 'Other recommended actions: Vaccinate if indicated'",no,Justification not provided,no,"Burundi 2020.10 PLAN DE MISE EN OEUVRE DES DIRECTIVES DE TARV 2020_VF PREFACEE_09 Oct 2020.fr.en.pdf: Page 63, Appendix 1 mentions 'Assessment and treatment of STIs' and 'Diagnosis and treatment of STIs', but does not specify 'Syphilis' or 'Treponema pallidum' as per the instruction to record only specific pathogens.",no,"Burundi 2020.10 PLAN DE MISE EN OEUVRE DES DIRECTIVES DE TARV 2020_VF PREFACEE_09 Oct 2020.fr.en.pdf: Page 63, Appendix 1 mentions 'Assessment and treatment of STIs' and 'Diagnosis and treatment of STIs', but does not specify 'Neisseria gonorrhoeae' or 'gonorrhea' as per the instruction to record only specific pathogens.",no,"Burundi 2020.10 PLAN DE MISE EN OEUVRE DES DIRECTIVES DE TARV 2020_VF PREFACEE_09 Oct 2020.fr.en.pdf: Page 63, Appendix 1 mentions 'Assessment and treatment of STIs' and 'Diagnosis and treatment of STIs', but does not specify 'Chlamydia trachomatis' or 'Chlamydia' as per the instruction to record only specific pathogens."
KHM,Cambodia,no,Justification not provided,yes,"2022 - nchads-sop-prep-implementation-cambodia-2022.pdf: Page 13, Figure 3: 'HBV' testing at 2nd Screening; Page 14, 4.2.5 CBO Drop-in-Centers: 'Rapid screening tests for ... HBsAg ... will be done in the CBO DIC'",ERR: no (REF: yes),Justification not provided,no,Justification not provided,yes,"2022 - nchads-sop-prep-implementation-cambodia-2022.pdf: Page 13, Figure 3: 'Syphilis' listed under 'Follow up (M3) & every 3 months'; Page 14, PrEP clients need to return...: 'HIV and syphilis testing'; Page 14, 4.2.5 CBO Drop-in-Centers: 'Rapid screening tests for ... syphilis will be done in the CBO DIC'",ERR: no (REF: yes),"2022 - nchads-sop-prep-implementation-cambodia-2022.pdf: Not mentioned specifically by pathogen (Neisseria gonorrhoeae) or disease (gonorrhoea), only general 'STI screening'",ERR: no (REF: yes),"2022 - nchads-sop-prep-implementation-cambodia-2022.pdf: Not mentioned specifically by pathogen (Chlamydia trachomatis) or disease (Chlamydia), only general 'STI screening'"
CMR,Cameroon,ERR: yes (REF: no),"Cadre de MEO de la Prophylaxie Pré exposition_Final 29042019.pdf: Page 37, 'Checklist Follow-Up Counselling', under 'Intimate partner violence (IPV)', states: 'People who have abusive or controlling partners may find it more difficult to take care of their sexual health and to adhere to PrEP. Ask about the client's relationships, and for clients experiencing abuse, provide counseling and referrals, when possible.'",yes,"Cadre de MEO de la Prophylaxie Pré exposition_Final 29042019.pdf: Page 11, 'Tests biologiques suivants seront réalisés, à l'initiation, à la charge du programme : Test diagnostic des hépatites'; Page 13, Figure 1. Suivi et paquet de service, 'PrEP Initiation: Hepatitis B Test'; Page 21, 'Budget CHAMP', 'HepB testing'.",ERR: yes (REF: no),"Cadre de MEO de la Prophylaxie Pré exposition_Final 29042019.pdf: Page 11, 'Tests biologiques suivants seront réalisés, à l'initiation, à la charge du programme : ... Test diagnostic des hépatites puis référence pour vaccination si négatif'.",no,Cadre de MEO de la Prophylaxie Pré exposition_Final 29042019.pdf: Not found.,ERR: yes (REF: no),"Cadre de MEO de la Prophylaxie Pré exposition_Final 29042019.pdf: Page 11, 'Tests biologiques des IST (syphilis)'; Page 13, Figure 1. Suivi et paquet de service, 'M0, M3, M6, M9, M12: Syphilis Testing + Treatment'; Page 21, 'Budget CHAMP', 'Syphilis test'.",no,"Cadre de MEO de la Prophylaxie Pré exposition_Final 29042019.pdf: The document mentions 'dépistage syndromique des IST' (Page 11, 13, 15) and symptoms like 'écoulement urétral/vaginal' (Page 11), but does not explicitly name Neisseria gonorrhoeae or gonorrhoea for specific pathogen screening/testing.",no,"Cadre de MEO de la Prophylaxie Pré exposition_Final 29042019.pdf: The document mentions 'dépistage syndromique des IST' (Page 11, 13, 15) and symptoms like 'écoulement urétral/vaginal' (Page 11), but does not explicitly name Chlamydia trachomatis or Chlamydia for specific pathogen screening/testing."
CAN,Canada,ERR: no (REF: yes),Justification not provided,yes,"Canada_PrEP guidelines 2017.pdf: Page 5, Box 4: ""Hepatitis A, B and C serologies should be performed at baseline""; Page 6, Table 3: ""Hepatitis B screen (surface antigen, surface antibody, core antibody)"" at baseline and Q12mo.",yes,"Canada_PrEP guidelines 2017.pdf: Page 5, Box 4: ""...with vaccination for hepatitis A and B for nonimmune individuals""",no,Justification not provided,yes,"Canada_PrEP guidelines 2017.pdf: Page 5, Box 4: ""Laboratory screening for sexually transmitted infections is suggested at baseline and at each quarterly follow-up visit""; Page 6, Table 3: ""Syphilis serology"" at baseline and Q3mo.",yes,"Canada_PrEP guidelines 2017.pdf: Page 5, Box 4: ""Laboratory screening for sexually transmitted infections is suggested at baseline and at each quarterly follow-up visit""; Page 6, Table 3: ""Screening for gonorrhea and chlamydia"" at baseline and Q3mo.",yes,"Canada_PrEP guidelines 2017.pdf: Page 5, Box 4: ""Laboratory screening for sexually transmitted infections is suggested at baseline and at each quarterly follow-up visit""; Page 6, Table 3: ""Screening for gonorrhea and chlamydia"" at baseline and Q3mo."
CUB,Cuba,yes,"Resolucion Ministerial No. 56 del 2019.pdf: Page 181, Section 2.a), 4th bullet point: 'Debe ofrecérsele al usuario la oportunidad que sus parejas sexuales puedan acudir a la consulta para descartar infecciones por VIH u otras ITS;'",yes,"Resolucion Ministerial No. 56 del 2019.pdf: Page 179, 'Indicación de complementarios', 2nd main bullet point regarding 'Descartar infección por el virus de la hepatitis B y C': 'Si VHB, HBsAG con positivo, contactar al paciente con el gastroenterólogo para seguimiento...'",yes,"Resolucion Ministerial No. 56 del 2019.pdf: Page 178, Section 2.b): 'Si no hay infección crónica por VHB, las personas susceptibles deben ser vacunadas frente a esta infección.'",no,Justification not provided,yes,"Resolucion Ministerial No. 56 del 2019.pdf: Page 179, 'Indicación de complementarios', 4th bullet point: 'Evaluación de ITS: serología VDRL, para descartar sífilis.'",yes,"Resolucion Ministerial No. 56 del 2019.pdf: Page 114, Section 2.3.d): 'Tamizaje para Neisseria gonorrhoeae (Ng) / Chlamydia trachomatis (Ct).'",yes,"Resolucion Ministerial No. 56 del 2019.pdf: Page 114, Section 2.3.d): 'Tamizaje para Neisseria gonorrhoeae (Ng) / Chlamydia trachomatis (Ct).'"
CZE,Czech Republic,no,"CZE PrEP Guidelines ENG.pdf: The document mentions 'diagnosis of STDs in the client or partner' as a trigger for PrEP (Page 14), and 'for the treatment of eventual STDs' (Page 5), but does not explicitly describe partner testing, partner treatment, or contact tracing services for STIs (excluding HIV) in the context of a partner having an STI.",yes,"CZE PrEP Guidelines ENG.pdf: Page 5, 'Initial examination: hepatitis serology examination (HBsAg, anti-HCV...)'; Page 7, 'Follow-up visits: testing for hepatitis in seronegative subjects once a year (HBsAg, anti-HCV)' and 'STD screening once every 6 months, anti-HCV and HBsAg testing for seronegative persons once a year are also mandatory.'",yes,"CZE PrEP Guidelines ENG.pdf: Page 4, 'Initial examination: vaccinations completed (including compulsory hepatitis B vaccination for persons born in 1989 and later)'; Page 5, 'agreement on the method of communicating the results of the initial examinations and the resulting recommendations: for vaccination against hepatitis A and B' and 'Clients who have not had hepatitis B should be offered vaccination.'",no,Justification not provided,yes,"CZE PrEP Guidelines ENG.pdf: Page 5, 'Initial examination: Examination for sexually transmitted diseases: syphilis screening serologically by a combination of one nontreponemal and one treponemal test'; Page 7, 'Follow-up visits: examination for sexually transmitted diseases at least every 6 months, optimal is every 3 months: syphilis screening serologically by a combination of one nontreponemal and one treponemal test'.",yes,"CZE PrEP Guidelines ENG.pdf: Page 5, 'Initial examination: Examination for sexually transmitted diseases: PCR Chlamydia trachomatis and Neisseria gonorrheae in rectum, throat and urethra swabs'; Page 7, 'Follow-up visits: examination for sexually transmitted diseases... PCR Chlamydia trachomatis and Neisseria gonorrheae in rectum, throat and urethra swabs'.",yes,"CZE PrEP Guidelines ENG.pdf: Page 5, 'Initial examination: Examination for sexually transmitted diseases: PCR Chlamydia trachomatis and Neisseria gonorrheae in rectum, throat and urethra swabs'; Page 7, 'Follow-up visits: examination for sexually transmitted diseases... PCR Chlamydia trachomatis and Neisseria gonorrheae in rectum, throat and urethra swabs'."
CIV,Côte d'Ivoire,no,Justification not provided,yes,"CDI_National PrEP Guidelines.pdf: Page 6, section 'Principes de base', subsection 'Bilan de santé initial': 'Rechercher une Hépatite virale B'; Page 9, section 'Examen biologique avant la mise sous PrEP', subsection 'Dépistage VHB': 'le dépistage de l'hépatite est obligatoire avant la mise sous traitement'.",yes,"CDI_National PrEP Guidelines.pdf: Page 9, section 'Examen biologique avant la mise sous PrEP', subsection 'Dépistage VHB': 'La vaccination devra être faite pour les personnes AgHBs négatif'.",no,Justification not provided,no,"CDI_National PrEP Guidelines.pdf: Only general 'IST' screening is mentioned without specifying 'syphilis' or 'Treponema pallidum'. Page 6, section 'Principes de base', subsection 'Bilan de santé initial': 'Détecter une infection à VIH et/ou une autre IST'; Page 9, section 'Examen biologique avant la mise sous PrEP', subsection 'Dépistage des IST'; Page 14, table 'Rechercher les IST selon l'algorithme national'.",no,"CDI_National PrEP Guidelines.pdf: Only general 'IST' screening is mentioned without specifying 'Neisseria gonorrhoeae' or 'gonorrhoea'. Page 6, section 'Principes de base', subsection 'Bilan de santé initial': 'Détecter une infection à VIH et/ou une autre IST'; Page 9, section 'Examen biologique avant la mise sous PrEP', subsection 'Dépistage des IST'; Page 14, table 'Rechercher les IST selon l'algorithme national'.",no,"CDI_National PrEP Guidelines.pdf: Only general 'IST' screening is mentioned without specifying 'Chlamydia trachomatis' or 'Chlamydia'. Page 6, section 'Principes de base', subsection 'Bilan de santé initial': 'Détecter une infection à VIH et/ou une autre IST'; Page 9, section 'Examen biologique avant la mise sous PrEP', subsection 'Dépistage des IST'; Page 14, table 'Rechercher les IST selon l'algorithme national'."
KOR,Korea,no,Justification not provided,yes,"ic-49-243.pdf: Page 3, Section 4, Point 3: 'Testing for hepatitis B virus (HBs Ag, HBs Ab) and hepatitis C virus (HCV Ab) should be performed before starting PrEP (AIII).'",yes,"ic-49-243.pdf: Page 3, Section 4, Point 3: 'Hepatitis B virus vaccination is recommended for MSM without HBs Ab (AIII).'",no,Justification not provided,yes,"ic-49-243.pdf: Page 3, Section 5, Point 7: 'Sexually active persons receiving PrEP should be seen at least every 6 months to conduct tests for sexually transmitted infections (i.e., syphilis, gonorrhea, chlamydia) (BII).'; Page 3, Table 2: 'Testing for sexually transmitted diseases (syphilis, gonorrhea, chlamydia, etc.)'",yes,"ic-49-243.pdf: Page 3, Section 5, Point 7: 'Sexually active persons receiving PrEP should be seen at least every 6 months to conduct tests for sexually transmitted infections (i.e., syphilis, gonorrhea, chlamydia) (BII).'; Page 3, Table 2: 'Testing for sexually transmitted diseases (syphilis, gonorrhea, chlamydia, etc.)'",yes,"ic-49-243.pdf: Page 3, Section 5, Point 7: 'Sexually active persons receiving PrEP should be seen at least every 6 months to conduct tests for sexually transmitted infections (i.e., syphilis, gonorrhea, chlamydia) (BII).'; Page 3, Table 2: 'Testing for sexually transmitted diseases (syphilis, gonorrhea, chlamydia, etc.)'"
COD,Democratic Republic of Congo,no,Justification not provided,yes,"DRC_National PrEP Guidelines.pdf: Page 34, section 2.4.4 'Il est recommandé de rechercher l'hépatite B virale chez tout client à la PrEP :'; Page 36, Figure 6; Page 43, Tableau 9 'Sérologie pour hépatite B'",yes,"DRC_National PrEP Guidelines.pdf: Page 34, section 2.4.4 'Si le test AgHBs est négatif : vacciné contre le virus de l'hépatite B'; Page 38, Tableau 6 'Proposer la vaccination contre le VHB si nécessaire'",no,Justification not provided,yes,"DRC_National PrEP Guidelines.pdf: Page 36, Figure 6 'Syphilis'; Page 43, Tableau 9 'Sérologie de la syphilis' at initial and 12 months; Page 43, Tableau 8 'Recherche des IST (gonorrhée, chlamydia, syphilis) lors du bilan initial puis à chaque visite'",yes,"DRC_National PrEP Guidelines.pdf: Page 43, Tableau 9 'Dépistage de la gonorrhée, de la chlamydia, (MSM) et les autres groupes, dépistage selon le facteur de risque' at initial and 12 months; Page 43, Tableau 8 'Recherche des IST (gonorrhée, chlamydia, syphilis) lors du bilan initial puis à chaque visite'",yes,"DRC_National PrEP Guidelines.pdf: Page 43, Tableau 9 'Dépistage de la gonorrhée, de la chlamydia, (MSM) et les autres groupes, dépistage selon le facteur de risque' at initial and 12 months; Page 43, Tableau 8 'Recherche des IST (gonorrhée, chlamydia, syphilis) lors du bilan initial puis à chaque visite'"
DNK,Denmark,no,Justification not provided,yes,"regionale_prep_anbefalinger_(2019) Denmark PrEP policy.da.en.pdf: Page 4, 'Survey for: island Hepatitis A + B + C'; Page 5, 'hepatitis A, B and C are tested every 6 months' including 'HBs antigen' for previously uninfected individuals.",yes,"regionale_prep_anbefalinger_(2019) Denmark PrEP policy.da.en.pdf: Page 4, 'In case of negative Hepatitis A and / or B serology, vaccination should be offered'.",no,Justification not provided,yes,"regionale_prep_anbefalinger_(2019) Denmark PrEP policy.da.en.pdf: Page 4, 'Survey for: island Syphilis' prior to treatment; Page 5, 'Syphilis test' every 3 months during follow-up.",yes,"regionale_prep_anbefalinger_(2019) Denmark PrEP policy.da.en.pdf: Page 4, 'Survey for: island Gonorrhea (urethra, pharynx and rectum)' prior to treatment; Page 5, 'Screening for chlamydia and gonorrhea' every 3 months during follow-up.",yes,"regionale_prep_anbefalinger_(2019) Denmark PrEP policy.da.en.pdf: Page 4, 'Survey for: island Chamydia (urethra, pharynx and rectum)' prior to treatment; Page 5, 'Screening for chlamydia and gonorrhea' every 3 months during follow-up."
ECU,Ecuador,no,Justification not provided,yes,"gpc_VIH_acuerdo_ministerial05-07-2019.pdf: Page 144, Anexo 2: 'Infección documentada por Hepatitis B y estado de vacunación' implies screening for Hepatitis B status before PrEP initiation.",ERR: yes (REF: no),"gpc_VIH_acuerdo_ministerial05-07-2019.pdf: Page 144, Anexo 2: 'Infección documentada por Hepatitis B y estado de vacunación' implies a recommendation for vaccination if not already immune.",no,"gpc_VIH_acuerdo_ministerial05-07-2019.pdf: Human Papillomavirus (HPV) vaccination is recommended on page 84 for HIV-infected individuals, but not specifically for PrEP users.",no,"gpc_VIH_acuerdo_ministerial05-07-2019.pdf: Page 25 recommends 'Realizar mandatoriamente testeo de VIH e ITS cada 3 meses' for PrEP users, and page 144 mentions 'test para ITSs bacterial'. However, neither explicitly specifies screening for syphilis by name for PrEP users.",no,"gpc_VIH_acuerdo_ministerial05-07-2019.pdf: Page 25 recommends 'Realizar mandatoriamente testeo de VIH e ITS cada 3 meses' for PrEP users, and page 144 mentions 'test para ITSs bacterial'. However, neither explicitly specifies screening for Neisseria gonorrhoeae by name for PrEP users.",no,"gpc_VIH_acuerdo_ministerial05-07-2019.pdf: Page 25 recommends 'Realizar mandatoriamente testeo de VIH e ITS cada 3 meses' for PrEP users, and page 144 mentions 'test para ITSs bacterial'. However, neither explicitly specifies screening for Chlamydia trachomatis by name for PrEP users."
SLV,El Salvador,no,"El_Salvador_lineamientostecnicosparalaprofilaxispreexposicionalvihprep-Acuerdo-2950 copy.pdf: The document mentions 'Pareja serodiscordante' (serodiscordant couple) in the context of HIV and conception (Page 24, point 5i; Page 32, point d), which refers to HIV, not other STIs as per the definition. No mention of partner testing, treatment, or contact tracing for non-HIV STIs was found.",yes,"El_Salvador_lineamientostecnicosparalaprofilaxispreexposicionalvihprep-Acuerdo-2950 copy.pdf: Page 26, 'Perfil de Laboratorio clínico basal en consulta inicial para evaluación de ingreso a PrEP': 'El perfil comprende pruebas para ITS (VIH, Sífilis, Hepatitis virales B y C...'. Also, Anexo 2 (Page 50) lists 'Virus de Hepatitis B (VHB)' for basal/reinicio and 6-month follow-up.",ERR: yes (REF: no),"El_Salvador_lineamientostecnicosparalaprofilaxispreexposicionalvihprep-Acuerdo-2950 copy.pdf: Page 26, 'Paso 1: Consulta inicial para evaluación de ingreso a PrEP', point 'Establecer el estatus de vacunación para el Virus de Hepatitis B.'",no,"El_Salvador_lineamientostecnicosparalaprofilaxispreexposicionalvihprep-Acuerdo-2950 copy.pdf: HPV (VPH) is listed for screening in Anexo 2 (Page 51) and Page 30, but there is no mention of HPV vaccination.",yes,"El_Salvador_lineamientostecnicosparalaprofilaxispreexposicionalvihprep-Acuerdo-2950 copy.pdf: Page 26, 'Perfil de Laboratorio clínico basal en consulta inicial para evaluación de ingreso a PrEP': 'El perfil comprende pruebas para ITS (VIH, Sífilis, Hepatitis virales B y C...'. Also, Anexo 2 (Page 50) lists 'Sífilis' for basal/reinicio and 3, 6, 9-month follow-up.",yes,"El_Salvador_lineamientostecnicosparalaprofilaxispreexposicionalvihprep-Acuerdo-2950 copy.pdf: Page 26, 'Perfil de Laboratorio clínico basal en consulta inicial para evaluación de ingreso a PrEP': 'El perfil comprende pruebas para ITS (... Neisseria g....'. Also, Anexo 2 (Page 51) lists 'Neisseria g.' for basal/reinicio. Page 30 explicitly mentions 'Neisseria g.' for annual screening in follow-up.",yes,"El_Salvador_lineamientostecnicosparalaprofilaxispreexposicionalvihprep-Acuerdo-2950 copy.pdf: Page 26, 'Perfil de Laboratorio clínico basal en consulta inicial para evaluación de ingreso a PrEP': 'El perfil comprende pruebas para ITS (... Chlamydia t....'. Also, Anexo 2 (Page 51) lists 'Chlamydia t.' for basal/reinicio. Page 30 explicitly mentions 'Chlamydia t.' for annual screening in follow-up."
ERI,Eritrea,no,"Eritrea PrEP guidelines 2019-Ministry of Health.pdf: Partner management mentioned only in the context of HIV, not other STIs for PrEP users. (Page 8)",yes,"Eritrea PrEP guidelines 2019-Ministry of Health.pdf: Table 3, Page 24: 'Hepatitis B surface antigen (HBsAg) screening prior to PrEP initiation'. Also, Page 29: 'every PrEP user should be tested for hepatitis B surface antigen (HBsAg)'.",no,Justification not provided,no,Justification not provided,no,"Eritrea PrEP guidelines 2019-Ministry of Health.pdf: The document only mentions 'Diagnosis and treatment of sexually transmitted infection' or 'STI screening' without specifying syphilis or Treponema pallidum. (Page 14, Page 24, Page 27)",no,"Eritrea PrEP guidelines 2019-Ministry of Health.pdf: The document only mentions 'Diagnosis and treatment of sexually transmitted infection' or 'STI screening' without specifying Neisseria gonorrhoeae or gonorrhoea. (Page 14, Page 24, Page 27)",no,"Eritrea PrEP guidelines 2019-Ministry of Health.pdf: The document only mentions 'Diagnosis and treatment of sexually transmitted infection' or 'STI screening' without specifying Chlamydia trachomatis or Chlamydia. (Page 14, Page 24, Page 27)"
EST,Estonia,no,"HIV_2019rj-hiv-web Translated.pdf: The document discusses assessing risk from sexual partners (e.g., their HIV status) for the individual considering PrEP (Page 13, Key recommendation 3; Page 17, paragraph 3; Page 55, Table 6). It mentions 'Recent bacterial STIs' as a risk factor for the PrEP user, but does not specify partner testing, treatment, or management services for non-HIV STIs.",yes,"HIV_2019rj-hiv-web Translated.pdf: Page 55, Table 6, 'Clinically suitable' section: 'Documented hepatitis B virus infection status (HBsAg, HBsAb, HBcAb)' is required before initiating PrEP.",ERR: yes (REF: no),"HIV_2019rj-hiv-web Translated.pdf: Page 55, Table 6, 'Clinically suitable' section: 'Documented hepatitis B virus infection status (HBsAg, HBsAb, HBcAb) and vaccination status' implies a recommendation for HBV vaccination at PrEP initiation.",no,HIV_2019rj-hiv-web Translated.pdf: Not found in the context of PrEP services/use.,no,"HIV_2019rj-hiv-web Translated.pdf: Page 56, Table 6, 'Others services' section, 'Regular follow-up visits': 'test for bacterial STIs every 3 to 6 months' is mentioned for PrEP follow-up, but it does not specify 'Treponema pallidum' or 'syphilis' for PrEP. Specific pathogen testing for syphilis (Treponema pallidum) is mentioned only for PEP in Table 7 (Page 57), which is explicitly excluded for PrEP.",no,"HIV_2019rj-hiv-web Translated.pdf: Page 56, Table 6, 'Others services' section, 'Regular follow-up visits': 'test for bacterial STIs every 3 to 6 months' is mentioned for PrEP follow-up, but it does not specify 'Neisseria gonorrhoeae' or 'gonorrhoea' for PrEP. Specific pathogen testing for gonorrhoea (N. gonorrhoeae DNA) is mentioned only for PEP in Table 7 (Page 57), which is explicitly excluded for PrEP.",no,"HIV_2019rj-hiv-web Translated.pdf: Page 56, Table 6, 'Others services' section, 'Regular follow-up visits': 'test for bacterial STIs every 3 to 6 months' is mentioned for PrEP follow-up, but it does not specify 'Chlamydia trachomatis' or 'Chlamydia' for PrEP. Specific pathogen testing for chlamydia (C. trachomatis DNA) is mentioned only for PEP in Table 7 (Page 57), which is explicitly excluded for PrEP."
SWZ,Eswatini,no,"Eswatini  PrEP Implementation guide.pdf: The document mentions disclosure to partner/family (page 13) and serodiscordant couples where one partner is HIV-positive (page 2, page 17), but does not mention partner testing, treatment, or management specifically for other STIs (excluding HIV).",yes,"Eswatini  PrEP Implementation guide.pdf: Page 12, 'PrEP minimum package' lists 'Hepatitis screening, creatinine clearance monitoring'. Page 13, 'INITIATION STEP' table, 'Hepatitis B surface antigen' section, discusses HBsAg testing. Page 25, 'Annex: Algorithm for PrEP initiation' includes 'Take baseline HBsAg test'.",yes,"Eswatini  PrEP Implementation guide.pdf: Page 13, 'INITIATION STEP' table, 'Hepatitis B surface antigen' section states: 'HBsAg negative: Offer hepatitis B vaccination if not previously completed at 0, 1, and 6 months (as per national hepatitis guidelines).'",no,Eswatini  PrEP Implementation guide.pdf: Not found.,no,"Eswatini  PrEP Implementation guide.pdf: The document mentions 'STI screening, diagnosis, and treatment' generally (page 12, page 19), but does not specify screening for syphilis or Treponema pallidum.",no,"Eswatini  PrEP Implementation guide.pdf: The document mentions 'STI screening, diagnosis, and treatment' generally (page 12, page 19), but does not specify screening for Neisseria gonorrhoeae or gonorrhoea.",no,"Eswatini  PrEP Implementation guide.pdf: The document mentions 'STI screening, diagnosis, and treatment' generally (page 12, page 19), but does not specify screening for Chlamydia trachomatis or Chlamydia."
ETH,Ethiopia,ERR: yes (REF: no),"PrEP Implementation manual (1).pdf: Page 14, Table 2, 'Counseling': 'To assess intimate partner violence and gender-based violence.'; Page 15, Table 3, 'Counseling': 'To assess intimate partner violence and gender based violence.'",yes,"PrEP Implementation manual (1).pdf: Page 12, 'Other important considerations': 'Testing for Hepatitis – B is mandatory before initiation and if a client is positive for Hepatitis B infection...'; Page 14, Table 2, 'Hepatitis B surface antigen: If negative, provide PrEP. If positive, refer for further testing...'; Page 16, Provider Checklist for Initial PrEP visit: 'Hepatitis B surface antigen (HBsAg)'. Page 19, Figure: PrEP Screening and Initiation Algorithm: 'Perform base line tests: HBsAg...'",no,Justification not provided,no,Justification not provided,no,"PrEP Implementation manual (1).pdf: Page 14, Table 2, 'Screening for sexually transmitted infection (STI)': 'To diagnose and treat STI (syndromic or diagnostic STI testing, depending on local guidelines).'; No specific pathogen like syphilis is mentioned.",no,"PrEP Implementation manual (1).pdf: Page 14, Table 2, 'Screening for sexually transmitted infection (STI)': 'To diagnose and treat STI (syndromic or diagnostic STI testing, depending on local guidelines).'; No specific pathogen like Neisseria gonorrhoeae is mentioned.",no,"PrEP Implementation manual (1).pdf: Page 14, Table 2, 'Screening for sexually transmitted infection (STI)': 'To diagnose and treat STI (syndromic or diagnostic STI testing, depending on local guidelines).'; No specific pathogen like Chlamydia trachomatis is mentioned."
FJI,Fiji,no,Justification not provided,yes,"HIV Care and Antiretroviral Therapy Guideline 3rd Edition 2022_Final Editable Version.pdf: Page 107, 'Test for other STIs, and Hepatis B'; Page 114, 'Test for other STI (e.g. syphilis and hepatitis)'",no,HIV Care and Antiretroviral Therapy Guideline 3rd Edition 2022_Final Editable Version.pdf: not found in PrEP specific sections,no,Justification not provided,yes,"HIV Care and Antiretroviral Therapy Guideline 3rd Edition 2022_Final Editable Version.pdf: Page 114, 'Test for other STI (e.g. syphilis and hepatitis)'; Page 115, '3 monthly blood tests for HIV, STI screening and pregnancy test'",no,"HIV Care and Antiretroviral Therapy Guideline 3rd Edition 2022_Final Editable Version.pdf: only general 'other STIs' mentioned, not specific pathogen for PrEP users",no,"HIV Care and Antiretroviral Therapy Guideline 3rd Edition 2022_Final Editable Version.pdf: only general 'other STIs' mentioned, not specific pathogen for PrEP users"
FIN,Finland,yes,"Finnish National PrEP guidelines 2019.fi.en.pdf: Page 16, paragraph 1: 'Both hepatitis A and B vaccines are available free of charge in public health, including injecting drug users, their loved ones, such as family members, sexual partners and partners, and men who have sex with men.'",yes,"Finnish National PrEP guidelines 2019.fi.en.pdf: Page 14, Table 7, 'HEPATITIS B STUDIES': 'S-HBsAg' is listed for 'BEFORE GETTING STARTED' and '12 KK'; Page 16, paragraph 1: 'Hepatitis A, B, and C antibodies and hepatitis B carrier (HbsAg) should be determined before initiating therapy.'",yes,"Finnish National PrEP guidelines 2019.fi.en.pdf: Page 14, Table 7, 'HEPATITIS B STUDIES': 'vaccination is recommended in the absence of protection'; Page 16, paragraph 1: 'Hepatitis A and B vaccination is recommended if a person is not protected against these diseases.'",no,Justification not provided,yes,"Finnish National PrEP guidelines 2019.fi.en.pdf: Page 14, Table 7, 'SYPHILIS': 'S-TrpaAb' is listed for 'BEFORE GETTING STARTED', '3 MONTHS', and 'OR END AFTER'; Page 16, paragraph 3: 'Chlamydia, gonorrhea and syphilis testing should be performed before starting treatment and every three months thereafter.'",yes,"Finnish National PrEP guidelines 2019.fi.en.pdf: Page 14, Table 7, 'KLAMYDIA AND TYPPIR': 'CtGcNhO' (Gc refers to Gonorrhea, Typpir is likely a typo/OCR error for Tippuri=Gonorrhea) is listed for 'BEFORE GETTING STARTED', '3 MONTHS', and 'OR END AFTER'; Page 15, footnote **: 'In addition to the chlamydia and gonorrhea urine sample, a sample must be taken from the throat if there has been oral sex and from the anus if there has been anal sex'; Page 16, paragraph 3: 'Chlamydia, gonorrhea and syphilis testing should be performed before starting treatment and every three months thereafter.'",yes,"Finnish National PrEP guidelines 2019.fi.en.pdf: Page 14, Table 7, 'KLAMYDIA AND TYPPIR': 'CtGcNhO' (Ct refers to Chlamydia) is listed for 'BEFORE GETTING STARTED', '3 MONTHS', and 'OR END AFTER'; Page 15, footnote **: 'In addition to the chlamydia and gonorrhea urine sample, a sample must be taken from the throat if there has been oral sex and from the anus if there has been anal sex'; Page 16, paragraph 3: 'Chlamydia, gonorrhea and syphilis testing should be performed before starting treatment and every three months thereafter.'"
FRA,France,no,"French guidelines experts-vih_prevention-depistage  2018.fr.en.pdf: While 'partner notification' is mentioned in general contexts, there is no specific recommendation for partner management, services, or contact tracing for STIs in the context of PrEP users' partners.",yes,"French guidelines experts-vih_prevention-depistage  2018.fr.en.pdf: Page 25, 'Methods of administration, monitoring and support for PrEP users', 'First consultation' section: 'The standard laboratory work-up should include tests for HIV, HAV, HBV, HCV and other STIs'. This is further detailed in Table 4 on Page 27, which lists 'HBV serology' for PrEP initiation and follow-up.",yes,"French guidelines experts-vih_prevention-depistage  2018.fr.en.pdf: Page 15, Box 3 ('Proposal for a screening strategy for sexually transmitted infections...'): 'HBV serologies and VHA followed by vaccination in case of negative serologies' for 'High risk men who have sex with men and transgender people', who are explicitly identified as PrEP target populations on page 24. This implies that if HBV serology is negative for PrEP users, vaccination is recommended.",yes,"French guidelines experts-vih_prevention-depistage  2018.fr.en.pdf: Page 29, 'Prevention of sexually transmitted infections through vaccination', 'HPV vaccination' section: 'access to the HPV vaccine should be systematically offered and available in CeGIDDs... to MSM up to the age of 26 years'. CeGIDDs are the primary centers for PrEP prescription, and MSM are a key target for PrEP.",yes,"French guidelines experts-vih_prevention-depistage  2018.fr.en.pdf: Page 25, 'Methods of administration, monitoring and support for PrEP users', 'First consultation' section: 'The standard laboratory work-up should include tests for HIV, HAV, HBV, HCV and other STIs'. Table 4 on Page 27 specifies 'STI screening $' with footnote: '$ gonococcal infection, chlamydia, syphilis'.",yes,"French guidelines experts-vih_prevention-depistage  2018.fr.en.pdf: Page 25, 'Methods of administration, monitoring and support for PrEP users', 'First consultation' section: 'The standard laboratory work-up should include tests for HIV, HAV, HBV, HCV and other STIs'. Table 4 on Page 27 specifies 'STI screening $' with footnote: '$ gonococcal infection, chlamydia, syphilis'.",yes,"French guidelines experts-vih_prevention-depistage  2018.fr.en.pdf: Page 25, 'Methods of administration, monitoring and support for PrEP users', 'First consultation' section: 'The standard laboratory work-up should include tests for HIV, HAV, HBV, HCV and other STIs'. Table 4 on Page 27 specifies 'STI screening $' with footnote: '$ gonococcal infection, chlamydia, syphilis'."
GEO,Georgia,no,"GEO PEP and PrEP Guidelines.pdf: The document discusses individual risk assessment, screening, and counseling for STIs for PrEP users, but does not explicitly mention partner(s) testing, treatment, management, services, or contact tracing in the context of one partner having an STI (excluding HIV).",yes,"GEO PEP and PrEP Guidelines.pdf: Page 11, Section 2.1.3 states: 'HBV serological status must be determined before PrEP initiation.' Page 17, Table 5, lists 'HBV serology (HBsAg, anti-HBc, anti-HBs)' for 'Initial Phase' and '6 Months' and '12 Months' follow-up.",yes,"GEO PEP and PrEP Guidelines.pdf: Page 11, Section 2.1.3 states: 'If HBV seromarkers are not detected, beneficiary should be offered hepatitis B vaccination'. Page 12, Table 1, under 'Meeting clinical criteria before PrEP initiation' lists 'Documented negative hepatitis B status and vaccination'. Page 29, Section 3.1.7.4 states: 'People who are especially vulnerable to HBV infection should be vaccinated'.",no,GEO PEP and PrEP Guidelines.pdf: Not found in the document.,yes,"GEO PEP and PrEP Guidelines.pdf: Page 11, Section 2.1.3 states: 'Screening for sexually transmitted infections is necessary before and during PrEP. This includes a serologic test for syphilis'. Page 17, Table 5, lists 'Serological test for syphilis' for 'Initial Phase' and '6 Months' and '12 Months' follow-up.",yes,"GEO PEP and PrEP Guidelines.pdf: Page 11, Section 2.1.3 states: 'Screening for sexually transmitted infections is necessary before and during PrEP. This includes ... nucleic acid-based molecular tests for gonorrhea and chlamydia'. Page 17, Table 5, lists 'Nucleic acid-based molecular test for gonorrhea and chlamydia' for 'Initial Phase' and '6 Months' and '12 Months' follow-up.",yes,"GEO PEP and PrEP Guidelines.pdf: Page 11, Section 2.1.3 states: 'Screening for sexually transmitted infections is necessary before and during PrEP. This includes ... nucleic acid-based molecular tests for gonorrhea and chlamydia'. Page 17, Table 5, lists 'Nucleic acid-based molecular test for gonorrhea and chlamydia' for 'Initial Phase' and '6 Months' and '12 Months' follow-up."
DEU,Germany,yes,"Austria -Germany Leitlinien zur PrEP_Stand 2018.pdf: Page 26, 'Abstimmung des Leitlinien-Gesamttexts' section, last sentence: 'Eine Partner*innen-Mitbehandlung wird empfohlen.'",yes,"Austria -Germany Leitlinien zur PrEP_Stand 2018.pdf: Page 15, Empfehlung 1.6, third bullet point: 'Ausschluss einer replikativen Hepatitis-B-Infektion mittels Serologie (HBs-Antigen, anti-HBc-Antikörper)'; Page 19, Table 2.1, row 'Hepatitis B*': 'X' for 'VOR PrEP Beginn', and '*=antiHBsAk, HBsAg, antiHBcAk'.",yes,"Austria -Germany Leitlinien zur PrEP_Stand 2018.pdf: Page 15, Empfehlung 1.6, third bullet point: 'Prüfung der HBV-Immunität (HBs-Antikörper, ggfs. Impfung gegen HBV)'; Page 16, Kommentar for Empfehlung 1.7, second paragraph: 'Die Prüfung der HBV-Immunität bei Abwesenheit einer Infektion sollte Anlass zur Überprüfung des gesamten Impfstatus und ggfs. der Komplettierung des Impfschutzes auch bezüglich HAV bei MSM sein, insbesondere aufgrund von bekannten Ausbruchssituationen in Europa [17,18].'",no,Justification not provided,yes,"Austria -Germany Leitlinien zur PrEP_Stand 2018.pdf: Page 19, Table 2.1, row 'Lues-Serologie': 'X' for 'VOR PrEP Beginn' and 'Alle 3 Monate' for 'Während PrEP'; Page 21, Kommentar for Empfehlung 2.1, third paragraph: 'Dazu werden regelmäßige 3-monatliche serologische Untersuchungen auf Syphilis... empfohlen.'",yes,"Austria -Germany Leitlinien zur PrEP_Stand 2018.pdf: Page 19, Table 2.1, row 'Gonorrhoe-NAAT**': 'X' for 'VOR PrEP Beginn' and 'Alle 3-6 Monate' for 'Während PrEP', with '**pharyngeal, anorektal, genital'; Page 21, Kommentar for Empfehlung 2.1, third paragraph: 'Abstrichuntersuchungen bei asymptomatischen PrEP-Nutzer*innen auf Chlamydia trachomatis und Neisseria gonorrhoeae (pharyngeal, genital und anorektal; ggfs. pooling möglich) werden alle 3-6 Monate empfohlen.'",yes,"Austria -Germany Leitlinien zur PrEP_Stand 2018.pdf: Page 19, Table 2.1, row 'Chlamydien-NAAT**': 'X' for 'VOR PrEP Beginn' and 'Alle 3-6 Monate' for 'Während PrEP', with '**pharyngeal, anorektal, genital'; Page 21, Kommentar for Empfehlung 2.1, third paragraph: 'Abstrichuntersuchungen bei asymptomatischen PrEP-Nutzer*innen auf Chlamydia trachomatis und Neisseria gonorrhoeae (pharyngeal, genital und anorektal; ggfs. pooling möglich) werden alle 3-6 Monate empfohlen.'"
GHA,Ghana,no,"Finale_CONSOLIDATED GUIDELINES FOR HIV CARE IN GHANA _booklet copy NEW FINAL (2).pdf: The PrEP section (Chapter Ten, pages 145-151) mentions 'STI prevention and management' broadly as part of the PrEP package (page 146), and family/partner testing for HIV (page 17, 38, 39), but does not explicitly detail partner(s) testing, treatment, management, services, or contact tracing for STIs (excluding HIV) in the context of PrEP users.",yes,"Finale_CONSOLIDATED GUIDELINES FOR HIV CARE IN GHANA _booklet copy NEW FINAL (2).pdf: Page 149, 'Summary of Pre-exposure prophylaxis visits and procedures': 'Conduct relevant laboratory tests—HIV test, Creatinine Clearance and HBsAg' and '3 monthly afterwards—HIV test, Pregnancy test, HBsAg (at 6 months only).'",no,"Finale_CONSOLIDATED GUIDELINES FOR HIV CARE IN GHANA _booklet copy NEW FINAL (2).pdf: Hepatitis B vaccination is mentioned for PEP survivors (page 158), but not explicitly for PrEP users.",no,"Finale_CONSOLIDATED GUIDELINES FOR HIV CARE IN GHANA _booklet copy NEW FINAL (2).pdf: HPV vaccination is recommended for adolescents among PLHIV (page 184), but not specifically for PrEP users or at PrEP initiation.",yes,"Finale_CONSOLIDATED GUIDELINES FOR HIV CARE IN GHANA _booklet copy NEW FINAL (2).pdf: Page 149, 'Summary of Pre-exposure prophylaxis visits and procedures': '6 monthly afterwards—CrCl, STI symptom screening, rapid syphilis test and HIV test.'",no,"Finale_CONSOLIDATED GUIDELINES FOR HIV CARE IN GHANA _booklet copy NEW FINAL (2).pdf: The document mentions 'STI symptom screening' (page 149) and 'STI treatment if indicated' (page 149) in the PrEP section, but does not specifically name Neisseria gonorrhoeae or gonorrhoea as a pathogen for screening.",no,"Finale_CONSOLIDATED GUIDELINES FOR HIV CARE IN GHANA _booklet copy NEW FINAL (2).pdf: The document mentions 'STI symptom screening' (page 149) and 'STI treatment if indicated' (page 149) in the PrEP section, but does not specifically name Chlamydia trachomatis or Chlamydia as a pathogen for screening."
GUY,Guyana,ERR: yes (REF: no),"PrEP Guyana Guidelines Final.pdf: Page 51, Annex 1, 'discussing HIV and STI status and/or testing with partner'",yes,"PrEP Guyana Guidelines Final.pdf: Page 21, 'Hepatitis B test'; Page 22, Table 1: Laboratory testing schedule at baseline and follow up, 'HBV (Hepatitis B surface antigen (HBsAg))'",yes,"PrEP Guyana Guidelines Final.pdf: Page 21, 'Hepatitis B test' ('If HBsAg is not detected, consider vaccination.'); Page 22, Table 1: Laboratory testing schedule at baseline and follow up, 'HBV (Hepatitis B surface antigen (HBsAg))' ('If HBsAg is not detected, consider vaccination.')",ERR: yes (REF: no),"PrEP Guyana Guidelines Final.pdf: Page 59, Annex 6: PROCEDURES WHEN INITIATING PREP (FIRST VISIT), 'Review vaccination history... consider vaccination for human papilloma virus.'",yes,"PrEP Guyana Guidelines Final.pdf: Page 21, 'Tests for Other Sexually Transmitted Infections such as for Syphilis'; Page 22, Table 1: Laboratory testing schedule at baseline and follow up, 'Syphilis (treponemal antibodies)' and 'Syphilis (rapid plasma reagintiter)'",yes,"PrEP Guyana Guidelines Final.pdf: Page 21, 'Tests for Other Sexually Transmitted Infections such as for ... Neisseria Gonorrhoea'; Page 22, Table 1: Laboratory testing schedule at baseline and follow up, 'Neisseria gonorrhoeae (GC)'",yes,"PrEP Guyana Guidelines Final.pdf: Page 21, 'Tests for Other Sexually Transmitted Infections such as for ... Chlamydia Trachomatis'; Page 22, Table 1: Laboratory testing schedule at baseline and follow up, 'Chlamydia trachomatis (CT)'"
HTI,Haiti,no,"PrEP_ Haiti Guidelines Final_.pdf: The document mentions partner management in the context of HIV (Page 9, Section 3.2) but not for other STIs (excluding HIV).",yes,"PrEP_ Haiti Guidelines Final_.pdf: Page 10, Section 4: 'Antigène HBs si disponible (antigène de surface de l'hépatite B)'; Page 11, Section 6: 'Dépistage du VIH, de la Syphilis et de l'Hépatite B (antigène HBs)'; Page 19, ANNEXE 4, section F: 'Date du test AgHBs'",ERR: yes (REF: no),"PrEP_ Haiti Guidelines Final_.pdf: Page 19, ANNEXE 4, section F: 'Si le résultat est positif le patient suit-il un traitement? vaccination VHB ☐ Oui ☐ Non ☐ Inconnu' and 'Si le résultat est négatif, quelles sont les dates de [vaccination VHB] qui ont été fournies'",no,"PrEP_ Haiti Guidelines Final_.pdf: Page 9, Section 3.2 mentions 'services de screening et de prise en charge des maladies sexuellement transmissibles comme la syphilis, la gonorrhée, le chlamydia, Human Papilloma Virus etc.' which refers to screening and management, not specifically vaccination for HPV. No direct recommendation for HPV vaccination for PrEP users was found.",yes,"PrEP_ Haiti Guidelines Final_.pdf: Page 9, Section 3.2: 'l'institution sanitaire puisse offrir les services de screening et de prise en charge des maladies sexuellement transmissibles comme la syphilis'; Page 10, Section 4: 'Tests de dépistage rapide du VIH et de la syphilis'; Page 11, Section 6: 'Dépistage du VIH, de la Syphilis...'; Page 20, ANNEXE 4, Section G: 'VDRL/test de dépistage de la syphilis'",yes,"PrEP_ Haiti Guidelines Final_.pdf: Page 9, Section 3.2: 'l'institution sanitaire puisse offrir les services de screening et de prise en charge des maladies sexuellement transmissibles comme la... gonorrhée'; Page 11, Section 6: 'Effectuer des tests d'IST recommandés pour toute personne sexuellement active (syphilis, gonorrhée, chlamydia).'",yes,"PrEP_ Haiti Guidelines Final_.pdf: Page 9, Section 3.2: 'l'institution sanitaire puisse offrir les services de screening et de prise en charge des maladies sexuellement transmissibles comme la... chlamydia'; Page 11, Section 6: 'Effectuer des tests d'IST recommandés pour toute personne sexuellement active (syphilis, gonorrhée, chlamydia).'"
HND,Honduras,no,"Honduras_LINEAMIENTOS PARA PROVEER LA PrEP RESOLUCION 2022 FINAL copy.pdf: The document mentions 'Parejas serodiscordantes' (page 9, 14, 20) only in the context of HIV status and risk, not for partner management, testing, or treatment of other STIs. No specific mention of contact tracing or partner services for STIs other than HIV.",yes,"Honduras_LINEAMIENTOS PARA PROVEER LA PrEP RESOLUCION 2022 FINAL copy.pdf: Figure 1 (Page 13) 'Intervenciones de prevención combinada' lists 'Cribado y tratamiento de ITS' and 'Vacunación de VHA, VHB, VPH'. Section 7.7.1.2.6 (Page 22) 'Exámenes laboratoriales adicionales' states: 'Antígeno de superficie del virus de Hepatitis B (HBsAg). Si los resultados son negativos para el VHB, considerar la vacunación contra el VHB.'. Anexo 2 (Page 41) 'Diagrama de flujo' lists 'Pruebas diagnósticas: VHB, VHC, Sífilis, otras ITS'. Anexo 6 (Page 45) 'Acciones a desarrollar' table includes 'Prueba diagnóstica para Hepatitis B' for initial and all follow-up consultations.",yes,"Honduras_LINEAMIENTOS PARA PROVEER LA PrEP RESOLUCION 2022 FINAL copy.pdf: Figure 1 (Page 13) 'Intervenciones de prevención combinada' lists 'Vacunación de VHA, VHB, VPH'. Section 7.7.1.3.2 (Page 22) 'Manejo o referencia de ITS si procede' states: 'considerar la vacunación contra la hepatitis A y VHB... según normativa nacional vigente.'. Anexo 6 (Page 45) 'Acciones a desarrollar' table includes 'Vacunar si procede según normas vigentes.' under 'Prueba diagnóstica para Hepatitis B' column 'Consulta inicial'.",ERR: yes (REF: no),"Honduras_LINEAMIENTOS PARA PROVEER LA PrEP RESOLUCION 2022 FINAL copy.pdf: Figure 1 (Page 13) 'Intervenciones de prevención combinada' lists 'Vacunación de VHA, VHB, VPH'. Section 7.7.1.3.2 (Page 22) 'Manejo o referencia de ITS si procede' states: 'considerar la vacunación contra... el virus del papiloma humano (VPH) según normativa nacional vigente.'",yes,"Honduras_LINEAMIENTOS PARA PROVEER LA PrEP RESOLUCION 2022 FINAL copy.pdf: Figure 1 (Page 13) 'Intervenciones de prevención combinada' lists 'Cribado y tratamiento de ITS'. Section 7.7.1.2.6 (Page 22) 'Exámenes laboratoriales adicionales' states: 'Prueba para diagnosticar y tratar la sífilis según normativa.'. Anexo 2 (Page 41) 'Diagrama de flujo' lists 'Pruebas diagnósticas: VHB, VHC, Sífilis, otras ITS'. Anexo 6 (Page 45) 'Acciones a desarrollar' table includes 'Pruebas diagnósticas para sífilis' for initial and all follow-up consultations. Anexo 7 (Page 46) 'Formulario' includes 'Sífilis' in the 'Infecciones de transmisión sexual (ITS)' section for 'Prueba realizada'.",ERR: yes (REF: no),"Honduras_LINEAMIENTOS PARA PROVEER LA PrEP RESOLUCION 2022 FINAL copy.pdf: Figure 1 (Page 13) 'Intervenciones de prevención combinada' lists 'Cribado y tratamiento de ITS'. Section 7.7.1.2.6 (Page 22) 'Exámenes laboratoriales adicionales' states: 'Otras pruebas de detección de ITS...'. Anexo 2 (Page 41) 'Diagrama de flujo' lists 'Pruebas diagnósticas: VHB, VHC, Sífilis, otras ITS'. Anexo 7 (Page 46) 'Formulario' explicitly lists 'Gonorrea' in the 'Infecciones de transmisión sexual (ITS)' section for 'Prueba realizada', implying it's covered under 'otras ITS'.",ERR: yes (REF: no),"Honduras_LINEAMIENTOS PARA PROVEER LA PrEP RESOLUCION 2022 FINAL copy.pdf: Figure 1 (Page 13) 'Intervenciones de prevención combinada' lists 'Cribado y tratamiento de ITS'. Section 7.7.1.2.6 (Page 22) 'Exámenes laboratoriales adicionales' states: 'Otras pruebas de detección de ITS...'. Anexo 2 (Page 41) 'Diagrama de flujo' lists 'Pruebas diagnósticas: VHB, VHC, Sífilis, otras ITS'. Anexo 7 (Page 46) 'Formulario' explicitly lists 'Clamidia' in the 'Infecciones de transmisión sexual (ITS)' section for 'Prueba realizada', implying it's covered under 'otras ITS'."
ISL,Iceland,no,Justification not provided,yes,"Iceland_PrEP_guidelines_2018.is.en.pdf: Page 1, 'Assessment before treatment and follow-up', 'Antibody testing against HIV, syphilis and hepatitis B and C'; Page 3, Figure 2 flowchart, 'Blood test at 11 weeks HIV, HBV, HCV, syphilis, create' and subsequent blood tests.",no,Justification not provided,no,Justification not provided,yes,"Iceland_PrEP_guidelines_2018.is.en.pdf: Page 1, 'Assessment before treatment and follow-up', 'Antibody testing against HIV, syphilis and hepatitis B and C'; Page 3, Figure 2 flowchart, 'Blood test at 11 weeks HIV, HBV, HCV, syphilis, create' and subsequent blood tests.",yes,"Iceland_PrEP_guidelines_2018.is.en.pdf: Page 1, 'Assessment before treatment and follow-up', 'Stroke from the throat, urethra and / or rectum measured by a nuclear acid test (PCR)'; Page 3, Figure 2 flowchart, 'Return on week 12 Chlamydia and gonorrhea Prescription renewal' and subsequent return visits.",yes,"Iceland_PrEP_guidelines_2018.is.en.pdf: Page 1, 'Assessment before treatment and follow-up', 'Stroke from the throat, urethra and / or rectum measured by a nuclear acid test (PCR)'; Page 3, Figure 2 flowchart, 'Return on week 12 Chlamydia and gonorrhea Prescription renewal' and subsequent return visits."
IND,India,yes,"India_NACO PrEP technical guidelines - May 2022 copy.pdf: Page 34, Table 'Possible causative organisms Drugs and Kits recommended for use', S.N. 1, 2, 3, 5.b, 7; Page 35, paragraph 'Whenever an STI is identified, treatment of partner/s must also be ensured.'; Page 51, 'STI Clinics' section, 'Strength' row: 'Experience with partner tracking, testing and treatment.'",yes,"India_NACO PrEP technical guidelines - May 2022 copy.pdf: Page 36, Table 'Investigations', 'HBsAg' row: 'To assess Hepatitis B, specifically in MSM, TG/TS and IDU population'.",yes,"India_NACO PrEP technical guidelines - May 2022 copy.pdf: Page 36, Table 'Investigations', 'HBsAg' row: 'If negative, consider vaccination against hepatitis B.'; Page 39, Table 'Summary', 'Initiation' section, 'Vaccination' row: 'Hepatitis B'; Page 48, 'Hepatitis B' section: 'Hepatitis B vaccination is recommended for people at substantial risk of HBV or HIV infection.'",yes,"India_NACO PrEP technical guidelines - May 2022 copy.pdf: Page 39, Table 'Summary', 'Initiation' section, 'Vaccination' row: 'Human papillomavirus vaccine (and expand on this)'.",yes,"India_NACO PrEP technical guidelines - May 2022 copy.pdf: Page 36, Table 'Investigations', 'VDRL/RPR' row: 'To rule out syphilis.'; Page 36, Table 'Investigations', 'STI screening' row: 'Screen for syphilis -RPR/VDRL Test.'; Page 35, paragraph 'In a laboratory setting...': 'RPR/VDRL might be considered for syphilis screening while NAAT test for chlamydia and gonorrhoea. ...M-PCR testing (for Tp,...)'.",yes,"India_NACO PrEP technical guidelines - May 2022 copy.pdf: Page 35, paragraph 'Modelling shows that more frequent testing in MSM PrEP users can result in a reduction in STI incidence – for gonorrhoea and chlamydia.'; Page 36, Table 'Investigations', 'STI screening' row: 'For MSM and TG/TS, NAAT testing is recommended for chlamydia and gonorrhoea using oral, rectal and urine specimen (M-PCR for Tp, Hd. HSV, Tv, Ng,Ct).'",yes,"India_NACO PrEP technical guidelines - May 2022 copy.pdf: Page 35, paragraph 'Modelling shows that more frequent testing in MSM PrEP users can result in a reduction in STI incidence – for gonorrhoea and chlamydia.'; Page 36, Table 'Investigations', 'STI screening' row: 'For MSM and TG/TS, NAAT testing is recommended for chlamydia and gonorrhoea using oral, rectal and urine specimen (M-PCR for Tp, Hd. HSV, Tv, Ng,Ct).'"
IDN,Indonesia,no,Justification not provided,yes,"Indonesia_Juknis PrEP_ENG.pdf: Page 31, Table 3.6 'Hepatitis B (HBsAg) service standards (paid by the program) Prerequisite for PrEP for potential MSM users choosing a PrEP-ED regimen'; Page 76, Appendix 6 'Hepatitis B (HBsAg) Baseline, outcome is not decisive following PrEP. All candidates PrEP users.'",yes,"Indonesia_Juknis PrEP_ENG.pdf: Page 32, 'If HBsAg is nonreactive but at risk for Hep B, recommend Hep B vaccine.'; Page 72, 'Hepatitis B test along with vaccination'; Page 76, Appendix 6 'Start PrEP. If HBsAg is nonreactive but at risk for Hep B, recommend Hep B vaccine.'",no,Justification not provided,yes,"Indonesia_Juknis PrEP_ENG.pdf: Page 31, Table 3.6 'IMS Syndromic examination and simple laboratory tests...should be done'; Page 74, section D 'Conduct serological tests for HIV, HCV, syphilis and other STI screening'; Page 76, Appendix 6 'STI examination with a simple laboratory (including syphilis)'",ERR: no (REF: yes),"Indonesia_Juknis PrEP_ENG.pdf: Specific pathogen 'Neisseria gonorrhoeae' or 'gonorrhoea' not explicitly mentioned for screening, only general 'STI tests' or 'syndromic approach'.",ERR: no (REF: yes),"Indonesia_Juknis PrEP_ENG.pdf: Specific pathogen 'Chlamydia trachomatis' or 'Chlamydia' not explicitly mentioned for screening, only general 'STI tests' or 'syndromic approach'."
IRN,Iran,no,Justification not provided,yes,"Iran_PEP_PreP Guideline_2017.ps.en.pdf: Page 28, paragraph 3. 'The individual should be diagnosed with hepatitis B after examination.'",yes,"Iran_PEP_PreP Guideline_2017.ps.en.pdf: Page 27, paragraph 2. 'Provider prEP There is an opportunity to increase access to other health services such as social support, hepatitis vaccination B'",no,"Iran_PEP_PreP Guideline_2017.ps.en.pdf: Page 26, last paragraph before '3- Pre-contact) : (PrEP)'. Recommendation is general, not tied to PrEP initiation.",ERR: no (REF: yes),"Iran_PEP_PreP Guideline_2017.ps.en.pdf: General STI assessment mentioned (Page 28), but no specific pathogen for syphilis screening recommended in the PrEP context.",no,"Iran_PEP_PreP Guideline_2017.ps.en.pdf: General STI assessment mentioned (Page 28), but no specific pathogen for Neisseria gonorrhoeae screening recommended in the PrEP context.",no,"Iran_PEP_PreP Guideline_2017.ps.en.pdf: General STI assessment mentioned (Page 28), but no specific pathogen for Chlamydia trachomatis screening recommended in the PrEP context."
IRL,Ireland,yes,"Ireland practical-prep-guidance-december-2017.pdf: Page 3, Section 2.1 'Partner notification'; Page 4, Section 2.1 'Partner notification'",yes,"Ireland practical-prep-guidance-december-2017.pdf: Page 7, Section 4.2.1 'HBV testing, directed by history'; Page 18, Section '3. Test for hepatitis B'",yes,"Ireland practical-prep-guidance-december-2017.pdf: Page 7, Section 4.1 'Hepatitis A, B (all)'; Page 7, Section 4.2.1 'Start HBV vaccination if immunity unknown'; Page 19, Section '4. Get vaccinated against hepatitis A and B'",yes,"Ireland practical-prep-guidance-december-2017.pdf: Page 7, Section 4.1 'HPV (<26 years)'",yes,"Ireland practical-prep-guidance-december-2017.pdf: Page 7, Section 4.2.1 'Syphilis serology'; Page 9, Section 4.2.2 'Syphilis serology'; Page 19, Section '6. Check for other sexually transmitted infections (STIs)'",yes,"Ireland practical-prep-guidance-december-2017.pdf: Page 7, Section 4.2.1 'Chlamydia and Gonorrhea NAAT testing'; Page 9, Section 4.2.2 'Chlamydia and Gonorrhea NAAT testing'; Page 19, Section '6. Check for other sexually transmitted infections (STIs)'",yes,"Ireland practical-prep-guidance-december-2017.pdf: Page 7, Section 4.2.1 'Chlamydia and Gonorrhea NAAT testing'; Page 9, Section 4.2.2 'Chlamydia and Gonorrhea NAAT testing'; Page 19, Section '6. Check for other sexually transmitted infections (STIs)'"
ISR,Israel,no,"Israel PrEP guidance.PDF: No specific mention of partner(s) testing, treatment, management, services, or contact tracing for STIs (excluding HIV).",yes,"Israel PrEP guidance.PDF: Page 2, 5th bullet point: 'המעקב אחר המטופל יכלול בדיקת ... הפטיטיס מסוג B (HBV)'. Page 6, section 3, 1st bullet point: 'יש לבדוק סטאטוס הדבקה ב-HBV בכלל המטופלים לפני תחילת הטיפול'. Page 8, 'טבלת בדיקות ומועדים לביצוען', under 'סרולוגיה להפטיטיס B' lists 'HBsAg (Hepatitis B surface Antigen)' for screening at initiation and periodically during treatment.",yes,"Israel PrEP guidance.PDF: Page 6, section 3, 2nd bullet point: 'למטופלים שלילים ל-HBV יש להציע חיסון לפני תחילת הטיפול.' (For patients negative for HBV, vaccination should be offered before starting treatment).",no,Justification not provided,yes,"Israel PrEP guidance.PDF: Page 4, last bullet point under 'יש ליעץ למטופלים על התנהגות מינית בטוחה אשר תכלול': 'בדיקות תכופות אחר מחלות מין ובדגש על עגבת...' (Frequent testing for other STIs with emphasis on syphilis...). Page 8, 'טבלת בדיקות ומועדים לביצוען', under 'בדיקות מחלות מין (עגבת, זיבה וכלמידה)' indicates testing at initiation and every six months.",yes,"Israel PrEP guidance.PDF: Page 4, last bullet point under 'יש ליעץ למטופלים על התנהגות מינית בטוחה אשר תכלול': 'בדיקות תכופות אחר מחלות מין ובדגש על ...זיבה...' (Frequent testing for other STIs with emphasis on ...gonorrhea...). Page 8, 'טבלת בדיקות ומועדים לביצוען', under 'בדיקות מחלות מין (עגבת, זיבה וכלמידה)' indicates testing at initiation and every six months.",yes,"Israel PrEP guidance.PDF: Page 4, last bullet point under 'יש ליעץ למטופלים על התנהגות מינית בטוחה אשר תכלול': 'בדיקות תכופות אחר מחלות מין ובדגש על ...וקלמידיה.' (Frequent testing for other STIs with emphasis on ...chlamydia). Page 8, 'טבלת בדיקות ומועדים לביצוען', under 'בדיקות מחלות מין (עגבת, זיבה וכלמידה)' indicates testing at initiation and every six months."
ITA,Italy,no,Justification not provided,yes,"Italy_Truvada Regulatory Approval_2019.it.en.pdf: Page 4, paragraph 3 under 'While taking Truvada to treat HIV or to reduce the risk of getting HIV': 'Find out if you are infected with the hepatitis B virus (HBV) before you start taking Truvada.'",ERR: no (REF: yes),Justification not provided,ERR: no (REF: yes),Justification not provided,ERR: yes (REF: no),"Italy_Truvada Regulatory Approval_2019.it.en.pdf: Page 3, paragraph under 'Simply taking Truvada may not stop you from contracting HIV': 'Get tested for other sexually transmitted infections such as syphilis and gonorrhea.'",ERR: yes (REF: no),"Italy_Truvada Regulatory Approval_2019.it.en.pdf: Page 3, paragraph under 'Simply taking Truvada may not stop you from contracting HIV': 'Get tested for other sexually transmitted infections such as syphilis and gonorrhea.'",no,Justification not provided
KAZ,Kazakhstan,ERR: yes (REF: no),"KAZ HIV Guidelines ENG.pdf: Page 99, 'Screening of both partners for STIs (and treatment if required) is mandatory.' in the context of 'Tips for HIV-discordant couples who want to have children.' PrEP is recommended for HIV-discordant couples on page 98.",ERR: yes (REF: no),"KAZ HIV Guidelines ENG.pdf: Page 30, section '10. Pre-exposure prophylaxis': 'It is recommended to test for STIs (including VH) at the beginning of PrEP and regularly during the use of PrEP, with the informed consent of the client.' VH refers to viral hepatitis, which includes HBV.",no,"KAZ HIV Guidelines ENG.pdf: The document recommends testing for VH (viral hepatitis) at PrEP initiation (Page 30), and general vaccination for susceptible patients (Page 55), but does not explicitly state a recommendation for HBV vaccination at PrEP initiation.",no,"KAZ HIV Guidelines ENG.pdf: HPV vaccination is only mentioned for HIV-positive patients (Page 56), not specifically for PrEP users.",yes,"KAZ HIV Guidelines ENG.pdf: Page 33, 'At least once every 6 months, for: ... STI screening behaviors for sexually active adolescents and adults (e.g., syphilis, gonorrhea, and chlamydia for both men and women, even if they are asymptomatic).' This explicitly mentions syphilis for PrEP users.",yes,"KAZ HIV Guidelines ENG.pdf: Page 33, 'At least once every 6 months, for: ... STI screening behaviors for sexually active adolescents and adults (e.g., syphilis, gonorrhea, and chlamydia for both men and women, even if they are asymptomatic).' This explicitly mentions gonorrhea for PrEP users.",yes,"KAZ HIV Guidelines ENG.pdf: Page 33, 'At least once every 6 months, for: ... STI screening behaviors for sexually active adolescents and adults (e.g., syphilis, gonorrhea, and chlamydia for both men and women, even if they are asymptomatic).' This explicitly mentions chlamydia for PrEP users."
KEN,Kenya,ERR: yes (REF: no),"Kenya-PrEP-Framework.pdf: Page 44, 'Access to Services' section: 'Determine strategies to promote and enhance partner testing and disclosure in PrEP settings.'",ERR: no (REF: yes),"Kenya-PrEP-Framework.pdf: The document mentions 'STI screening' (Page 46) and 'monitoring for sexually transmitted infections (STIs)' (Page 30), and 'Number of PrEP clients diagnosed with STI' (Page 48), but does not specify screening for Hepatitis B or HBsAg.",ERR: no (REF: yes),Justification not provided,no,Justification not provided,ERR: no (REF: yes),"Kenya-PrEP-Framework.pdf: The document mentions 'STI screening' (Page 46) and 'monitoring for sexually transmitted infections (STIs)' (Page 30), and 'Number of PrEP clients diagnosed with STI' (Page 48), but does not specify screening for syphilis or Treponema pallidum.",no,"Kenya-PrEP-Framework.pdf: The document mentions 'STI screening' (Page 46) and 'monitoring for sexually transmitted infections (STIs)' (Page 30), and 'Number of PrEP clients diagnosed with STI' (Page 48), but does not specify screening for Neisseria gonorrhoeae or gonorrhoea.",no,"Kenya-PrEP-Framework.pdf: The document mentions 'STI screening' (Page 46) and 'monitoring for sexually transmitted infections (STIs)' (Page 30), and 'Number of PrEP clients diagnosed with STI' (Page 48), but does not specify screening for Chlamydia trachomatis or Chlamydia."
KGZ,Kyrgyz Republic,no,Justification not provided,yes,"KGZ HIV Guidelines ENG.pdf: Page 12, Table 'Clinical monitoring for PrEP', row 'Test for HBV infection', column 'Note': 'The HBsAg test should be repeated every 12 months (if the initial result is negative, there is a risk of infection and vaccination is not performed).'",yes,"KGZ HIV Guidelines ENG.pdf: Page 12, Table 'Clinical monitoring for PrEP', row 'Test for HBV infection', column 'Note': 'Redirect the client to receiveHBV vaccination.'",no,"KGZ HIV Guidelines ENG.pdf: Recommendations for HPV vaccination are specified for 'People living with HIV' (PLHIV) on Page 20 and Page 26, not explicitly for PrEP users.",yes,"KGZ HIV Guidelines ENG.pdf: Page 11, Table 'Clinical monitoring for PrEP', row 'Testing for STIs', column 'Note': 'Testing for STIs (syphilis, chlamydia, trichomoniasis, gonorrhea) for sexually active people is carried out in accordance with current recommendations.'",yes,"KGZ HIV Guidelines ENG.pdf: Page 11, Table 'Clinical monitoring for PrEP', row 'Testing for STIs', column 'Note': 'Testing for STIs (syphilis, chlamydia, trichomoniasis, gonorrhea) for sexually active people is carried out in accordance with current recommendations.'",yes,"KGZ HIV Guidelines ENG.pdf: Page 11, Table 'Clinical monitoring for PrEP', row 'Testing for STIs', column 'Note': 'Testing for STIs (syphilis, chlamydia, trichomoniasis, gonorrhea) for sexually active people is carried out in accordance with current recommendations.'"
LAO,Lao PDR,ERR: yes (REF: no),"Lao PDR PrEP Guidelines_Print_EN version 2021.pdf: Table 2, row 'Mental health, gender-based violence (GBV), including intimate partner violence (IPV), and substance use screening and counselling', Page 27; and Page 32, Risk Reduction Counselling, paragraph 3 mentions addressing IPV.",yes,"Lao PDR PrEP Guidelines_Print_EN version 2021.pdf: Table 2, row 'HBV serology', Page 27; and Annex 1, Section G. Hepatitis B Testing, Vaccination, and Treatment, Page 43.",yes,"Lao PDR PrEP Guidelines_Print_EN version 2021.pdf: Table 2, footnote 26, Page 27 states 'HBsAg negative: offer hepatitis B vaccination (as per national hepatitis guidelines).'; and Annex 1, Section G. Hepatitis B Testing, Vaccination, and Treatment, Page 43 includes 'If negative, dates HBV vaccination provided:'.",no,Justification not provided,yes,"Lao PDR PrEP Guidelines_Print_EN version 2021.pdf: Table 2, footnote 23, Page 27 specifies 'STI screening (syphilis...)' and Annex 1, Section H. Sexually Transmitted Infections (STI), Page 43 lists 'VDRL/Syphilis test date:'.",yes,"Lao PDR PrEP Guidelines_Print_EN version 2021.pdf: Table 2, footnote 23, Page 27 specifies 'STI screening (...N gonorrhea...)'.",yes,"Lao PDR PrEP Guidelines_Print_EN version 2021.pdf: Table 2, footnote 23, Page 27 specifies 'STI screening (...C trachomatis)'."
LSO,Lesotho,no,Final Interactive -Lesotho HIV Prevention-Treatment and Care guideline (2022).pdf: Partner management for STIs (excluding HIV) specifically in the context of PrEP users is not explicitly mentioned. Partner services mentioned are primarily for HIV.,yes,"Final Interactive -Lesotho HIV Prevention-Treatment and Care guideline (2022).pdf: Page 19, Table 3.1 'Baseline Laboratory Tests for Clients Initiating PrEP' explicitly lists 'Hepatitis B surface antigen (HBsAg)' for screening. Also mentioned on Page 20, Table 3.3 'Initial Visit Assessment and Services for PrEP Clients' and 'Other baseline laboratory tests'.",ERR: yes (REF: no),"Final Interactive -Lesotho HIV Prevention-Treatment and Care guideline (2022).pdf: Page 19, Table 3.1 'Baseline Laboratory Tests for Clients Initiating PrEP' states 'To identify those eligible for vaccination against Hepatitis B'.",ERR: no (REF: yes),Final Interactive -Lesotho HIV Prevention-Treatment and Care guideline (2022).pdf: HPV vaccination is discussed in the document (Pages 67-68) but not specifically recommended at initiation or follow-up of PrEP services or for PrEP users.,yes,"Final Interactive -Lesotho HIV Prevention-Treatment and Care guideline (2022).pdf: Page 19, 'Unavailability of results for the following should not delay initiation on PrEP' lists 'RPR/VDRL'. Page 20, Table 3.3 'Initial Visit Assessment and Services for PrEP Clients' lists 'RPR/VDRL' under 'Laboratory Evaluation'. Page 20, 'Other baseline laboratory tests' states 'An RPR, Hepatitis B screen and pregnancy test must be performed on all new PrEP clients'.",no,"Final Interactive -Lesotho HIV Prevention-Treatment and Care guideline (2022).pdf: While 'gonorrhoea' is mentioned as a risk factor for HIV acquisition (Page 18, 'PrEP Eligibility'), there is no explicit recommendation to screen for Neisseria gonorrhoeae (NG) or gonorrhoea at initiation or follow-up of PrEP services/use for all PrEP users.",no,"Final Interactive -Lesotho HIV Prevention-Treatment and Care guideline (2022).pdf: While 'chlamydia' is mentioned as a risk factor for HIV acquisition (Page 18, 'PrEP Eligibility'), there is no explicit recommendation to screen for Chlamydia trachomatis (CT) or Chlamydia at initiation or follow-up of PrEP services/use for all PrEP users."
MYS,Malaysia,no,Justification not provided,yes,"Malaysian-Consensus-Guidelines-on-Antiretroviral-Therapy-2017-MINISTRY-OF-HEALTH-MALAYSIA.pdf: Page 86, Section 17.4, Point 3: Serology for Hepatitis A, B and C viruses (Hep A IgG, Hep BsAg, Hep B sAb and Hep C Ab)",yes,"Malaysian-Consensus-Guidelines-on-Antiretroviral-Therapy-2017-MINISTRY-OF-HEALTH-MALAYSIA.pdf: Page 86, Section 17.4, Point 3 bullet point: Hepatitis B vaccination should be provided to susceptible patients who are Hep B sAg and sAb neg",no,Justification not provided,yes,"Malaysian-Consensus-Guidelines-on-Antiretroviral-Therapy-2017-MINISTRY-OF-HEALTH-MALAYSIA.pdf: Page 86, Section 17.4, Point 4 bullet point: Rapid plasma reagin test for syphilis",yes,"Malaysian-Consensus-Guidelines-on-Antiretroviral-Therapy-2017-MINISTRY-OF-HEALTH-MALAYSIA.pdf: Page 86, Section 17.4, Point 4 bullet point: NAAT for gonococcal (GC) and chlamydial (CT) infections3-site screening",yes,"Malaysian-Consensus-Guidelines-on-Antiretroviral-Therapy-2017-MINISTRY-OF-HEALTH-MALAYSIA.pdf: Page 86, Section 17.4, Point 4 bullet point: NAAT for gonococcal (GC) and chlamydial (CT) infections3-site screening"
MLI,Mali,no,"Mali_NORMES-ET-PROTOCOLES-DE-PRISE-EN-CHARGE-ANTIRETROVIRALE_VALIDE_19-VF-070220-1.pdf: Page 80, under 'DEMARCHE PRÉALABLE', mentions checking for 'absence d'infections sexuellement transmissibles' in the partner for PrEP initiation, indicating partner status consideration. However, it does not explicitly detail ongoing partner testing, treatment, or management services when a PrEP user is diagnosed with an STI. The prompt specifically asks for 'partner(s) testing OR partner(s) treatment OR partner(s) management'.",yes,"Mali_NORMES-ET-PROTOCOLES-DE-PRISE-EN-CHARGE-ANTIRETROVIRALE_VALIDE_19-VF-070220-1.pdf: Page 81, under 'Consultation initiale: Jour 0', states 'Bilan VIH, IST et Hépatite B.', indicating screening for Hepatitis B at PrEP initiation.",no,"Mali_NORMES-ET-PROTOCOLES-DE-PRISE-EN-CHARGE-ANTIRETROVIRALE_VALIDE_19-VF-070220-1.pdf: The 'PROPHYLAXIE PRÉ-EXPOSITION' section (pages 80-82) does not explicitly mention Hepatitis B vaccination for PrEP users. While vaccination is mentioned in a general section for HIV-infected individuals (page 47), it is not specified for PrEP users.",no,Mali_NORMES-ET-PROTOCOLES-DE-PRISE-EN-CHARGE-ANTIRETROVIRALE_VALIDE_19-VF-070220-1.pdf: Human Papillomavirus (HPV) vaccination is not mentioned anywhere in the document.,no,"Mali_NORMES-ET-PROTOCOLES-DE-PRISE-EN-CHARGE-ANTIRETROVIRALE_VALIDE_19-VF-070220-1.pdf: Page 81, under 'Consultation initiale: Jour 0', 'Consultation de suivi 1 = Mois 1', and 'Consultation de suivi 3 = Mois 4', mention general 'IST' (Infections Sexuellement Transmissibles) screening for PrEP users. However, the document does not explicitly name syphilis or Treponema pallidum as a specific pathogen for screening in the context of PrEP.",no,"Mali_NORMES-ET-PROTOCOLES-DE-PRISE-EN-CHARGE-ANTIRETROVIRALE_VALIDE_19-VF-070220-1.pdf: Page 81, under 'Consultation initiale: Jour 0', 'Consultation de suivi 1 = Mois 1', and 'Consultation de suivi 3 = Mois 4', mention general 'IST' (Infections Sexuellement Transmissibles) screening for PrEP users. However, the document does not explicitly name Neisseria gonorrhoeae or gonorrhoea as a specific pathogen for screening in the context of PrEP.",no,"Mali_NORMES-ET-PROTOCOLES-DE-PRISE-EN-CHARGE-ANTIRETROVIRALE_VALIDE_19-VF-070220-1.pdf: Page 81, under 'Consultation initiale: Jour 0', 'Consultation de suivi 1 = Mois 1', and 'Consultation de suivi 3 = Mois 4', mention general 'IST' (Infections Sexuellement Transmissibles) screening for PrEP users. However, the document does not explicitly name Chlamydia trachomatis or Chlamydia as a specific pathogen for screening in the context of PrEP."
MEX,Mexico,no,"Mexico Gu_aARV_2019_09Noviembre.pdf: The document mentions 'diagnóstico y tratamiento de otras infecciones de transmisión sexual' and 'monitoreo de la salud sexual' as part of an integrated prevention package for PrEP users, but does not explicitly specify partner services (testing, treatment, or notification) in the context of a partner having an STI.",yes,"Mexico Gu_aARV_2019_09Noviembre.pdf: Page 86, paragraph 2 states: 'Se recomienda realizar una prueba de antígeno de superficie de la hepatitis B (HBsAg) antes de iniciar PrEP.'; Page 89, Table II-F, row 'VHB' indicates basal and follow-up screening for 'Persona expuesta'.",yes,"Mexico Gu_aARV_2019_09Noviembre.pdf: Page 87, Table II-D, under 'Intervención: Antígeno Hep B', 'Observaciones' column states: 'Negativo: considerar vacuna'.",ERR: no (REF: yes),"Mexico Gu_aARV_2019_09Noviembre.pdf: Page 119 and 121 mention HPV vaccination generally for people with HIV, but not specifically for PrEP users or at PrEP initiation.",yes,"Mexico Gu_aARV_2019_09Noviembre.pdf: Page 87, Table II-D, under 'Intervención: VDRL' states 'Diagnóstico y tratamiento de sífilis'; Page 89, Table II-F, row 'Sífilis' indicates basal and follow-up screening for 'Persona expuesta'.",ERR: yes (REF: no),"Mexico Gu_aARV_2019_09Noviembre.pdf: Page 89, Table II-F, row 'Gonorrea' indicates basal and follow-up screening for 'Persona expuesta'.",ERR: yes (REF: no),"Mexico Gu_aARV_2019_09Noviembre.pdf: Page 89, Table II-F, row 'Clamidia' indicates basal and follow-up screening for 'Persona expuesta'."
MDA,Moldova,ERR: yes (REF: no),"Moldova PrEP clinical protocol 2018.pdf: Page 13, Table 1, 'Consiliere': 'De evaluat violența partenerului intim precum și violența bazată pe factorul gender.'; Page 17, 'Consiliere în cadrul PrEP': 'violența din partea partenerului intim și abuzul de substanțe psiho-active.'",yes,"Moldova PrEP clinical protocol 2018.pdf: Page 13, Table 1, 'HBsAg': 'Dacă e negativ, de recomandat vaccinarea anti-HVB Dacă pozitiv, de recomandat testare suplimentară precum și aprecierea necesității tratamentului anti - hepatita B'; Page 23, 'Teste iniţiale': 'HBsAg – o dată pe an,'.",yes,"Moldova PrEP clinical protocol 2018.pdf: Page 13, Table 1, 'Anamneza vaccinelor suportate': 'de luat în considerare vaccinarea pentru HVB (HVA), papilloma virus uman.'; Page 23, 'Situații speciale': 'Dacă HBs Ag e negativ se recomandă vaccinare'.",ERR: yes (REF: no),"Moldova PrEP clinical protocol 2018.pdf: Page 13, Table 1, 'Anamneza vaccinelor suportate': 'de luat în considerare vaccinarea pentru HVB (HVA), papilloma virus uman.'",yes,"Moldova PrEP clinical protocol 2018.pdf: Page 13, Table 1, 'Teste de diagnostic al sifilisului': 'Diagnosticarea și tratamentul infecției sifilitice'; Page 23, 'Teste iniţiale': 'Screening ITS (Syphilis) – fiecare 6 luni'.",no,"Moldova PrEP clinical protocol 2018.pdf: The document mentions 'gonoreea' as an infection not prevented by PrEP (Page 17, C8. CONSILIERE ÎN CADRUL PREP), and general STI screening (Page 13, Table 1 'Screening suplimentar la ITS'; Page 17, 'La necesitate, de efectuat screening la ITS'), but does not explicitly recommend screening for 'Neisseria gonorrhoeae' or 'gonorrhea' by name of the pathogen in the context of screening tests.",no,"Moldova PrEP clinical protocol 2018.pdf: The document mentions 'chlamydia' as an infection not prevented by PrEP (Page 17, C8. CONSILIERE ÎN CADRUL PREP), and general STI screening (Page 13, Table 1 'Screening suplimentar la ITS'; Page 17, 'La necesitate, de efectuat screening la ITS'), but does not explicitly recommend screening for 'Chlamydia trachomatis' or 'chlamydia' by name of the pathogen in the context of screening tests."
MNG,Mongolia,ERR: yes (REF: no),"305 ENG.pdf: Page 70, Table 38, 'Duration of tracing and treating sexual partners of the patients with STIs' details tracing and treatment protocols for sexual partners of individuals diagnosed with specific STIs (excluding HIV), including Gonorrhea, Syphilis, and Trichomoniasis. These general STI guidelines apply within the overall context of the document which includes PrEP.",yes,"305 ENG.pdf: Page 136, under 'Control' in the PrEP section (Table 23), it states: 'Conduct HBV screening tests...'",yes,"305 ENG.pdf: Page 136, under 'Control' in the PrEP section (Table 23), it states: '...vaccinate regardless of the decision on PrEP...'",no,"305 ENG.pdf: Human Papillomavirus (HPV) vaccination is mentioned on page 116 for HIV-infected individuals as an opportunistic infection prevention, but not specifically for PrEP users.",no,"305 ENG.pdf: While general 'STI screening tests' are mentioned for PrEP users on page 136, syphilis or Treponema pallidum are not specifically named in that context.",no,"305 ENG.pdf: While general 'STI screening tests' are mentioned for PrEP users on page 136, Neisseria gonorrhoeae or gonorrhea are not specifically named in that context.",no,"305 ENG.pdf: While general 'STI screening tests' are mentioned for PrEP users on page 136, Chlamydia trachomatis or Chlamydia are not specifically named in that context."
MMR,Myanmar,no,"2023Aug_PrEP_SOP_Final_print.pdf: Not found. The document mentions protecting partners from HIV and assessing partner HIV risk factors, but no explicit recommendations for STI partner management (testing, treatment, or contact tracing) for STIs other than HIV, or management for partners in drug injecting or IPV contexts regarding STIs.",yes,"2023Aug_PrEP_SOP_Final_print.pdf: Page 17, 'Flow Chart for PrEP initiation' includes 'Draw blood for CrCl, HBsAg, STI and other tests'. Page 19, 'Table 3: Summary of Laboratory investigations for starting and monitoring PrEP' includes 'HBsAg'. Page 21, '4. Hepatitis B Infection' states 'All persons screened for PrEP should be tested for hepatitis B surface antigen (HBsAg) once, at or within one to three months of PrEP initiation.'",yes,"2023Aug_PrEP_SOP_Final_print.pdf: Page 19, 'Table 3: Summary of Laboratory investigations for starting and monitoring PrEP', HBsAg remark: 'If negative, consider vaccination against HBV.'. Page 21, '4. Hepatitis B Infection': 'Consider vaccination if HBsAg is not detected and there is no documented history of a completed vaccine series for Hepatitis B Virus (HBV).'",no,Justification not provided,yes,"2023Aug_PrEP_SOP_Final_print.pdf: Page 19, 'Table 3: Summary of Laboratory investigations for starting and monitoring PrEP' lists 'STI (Syphilis, GC, CT)' with a frequency of 'Every 6 months' and a remark 'Syndromic or diagnostic STI testing, according to National STI Management Guidelines.'",yes,"2023Aug_PrEP_SOP_Final_print.pdf: Page 19, 'Table 3: Summary of Laboratory investigations for starting and monitoring PrEP' lists 'STI (Syphilis, GC, CT)' with 'GC' referring to gonorrhoea (confirmed on Page 27, '[PrEP does not prevent syphilis, gonorrhoea, chlamydia, trichomonas or chancroid.]').",yes,"2023Aug_PrEP_SOP_Final_print.pdf: Page 19, 'Table 3: Summary of Laboratory investigations for starting and monitoring PrEP' lists 'STI (Syphilis, GC, CT)' with 'CT' referring to chlamydia (confirmed on Page 27, '[PrEP does not prevent syphilis, gonorrhoea, chlamydia, trichomonas or chancroid.]')."
MKD,Northern Macedonia,no,Justification not provided,yes,"MKD PrEP Guidelines ENG.pdf: Page 11, paragraph 3: 'Serological examination for viral hepatitis B and C is also important in the context of starting PrEP. If the hepatitis B screening test is negative, the person wishing to start PrEP could benefit from hepatitis B vaccination (20); if the test result is positive, the person may undergo further blood tests to determine whether hbv infection (23,24) would be appropriate.'; Page 17, Table 2: 'HBsAg ** (anti-HBs, if on the disposal)' at -1. or 0. Sunday.",yes,"MKD PrEP Guidelines ENG.pdf: Page 11, paragraph 3: 'If the hepatitis B screening test is negative, the person wishing to start PrEP could benefit from hepatitis B vaccination (20)'; Page 17, Table 2: 'HBV vaccination**' at -1. or 0. Sunday.",ERR: yes (REF: no),"MKD PrEP Guidelines ENG.pdf: Page 17, Table 2: 'HPV vaccination' at -1. or 0. Sunday.",yes,"MKD PrEP Guidelines ENG.pdf: Page 17, Table 2: 'Syphilis serologically' at -1. or 0. Sunday, 6. month, and 12. month.",yes,"MKD PrEP Guidelines ENG.pdf: Page 16, paragraph 2: 'Under the proposed pilot project in Skopje, molecular testing for gonorrhea and chlamydia will be provided, at the starting level, at 6. month, and at 12. month...'; Page 17, Table 2: 'N. gonorrhea PCR' at -1. or 0. Sunday, 6. month, and 12. month.",yes,"MKD PrEP Guidelines ENG.pdf: Page 16, paragraph 2: 'Under the proposed pilot project in Skopje, molecular testing for gonorrhea and chlamydia will be provided, at the starting level, at 6. month, and at 12. month...'; Page 17, Table 2: 'H. trachomatis PCR' at -1. or 0. Sunday, 6. month, and 12. month."
NAM,Namibia,no,"Namibia_national_guidelines_art.pdf: The document mentions PrEP for serodiscordant couples where one partner is HIV-positive (Page 98) and discusses HIV-related aspects, but it does not specify partner management for other STIs for PrEP users.",yes,"Namibia_national_guidelines_art.pdf: Page 99, Table 5.1: 'Screening and PrEP initiation: Tests—HIV test, CrCl, HBsAg' and 'Four-month follow-up and 3-monthly maintenance visits: Tests: HBsAg (at 6 months only)'",no,"Namibia_national_guidelines_art.pdf: Not found in the context of PrEP services/users. Hepatitis B vaccination is mentioned for PEP (Page 17), but not PrEP.",no,"Namibia_national_guidelines_art.pdf: Not found in the context of PrEP services/users. HPV vaccination is recommended for 'adolescents living with HIV' (Page 95, Section 4.3.2), not specifically for HIV-negative PrEP users.",yes,"Namibia_national_guidelines_art.pdf: Page 99, Table 5.1: 'Four-month follow-up and 3-monthly maintenance visits: Tests: rapid syphilis test'",no,"Namibia_national_guidelines_art.pdf: Not found for specific pathogen 'Neisseria gonorrhoeae' for PrEP users. 'STI symptom screening' (Page 99, Table 5.1) is too general.",no,"Namibia_national_guidelines_art.pdf: Not found for specific pathogen 'Chlamydia trachomatis' for PrEP users. 'STI symptom screening' (Page 99, Table 5.1) is too general."
NPL,Nepal,no,"National SOP HIV  PrEP-Nepal -Final _2022-NCASC Nepal.pdf: The document mentions discussing PrEP with partners and linkage to ART for HIV-positive partners, but does not explicitly recommend partner testing, treatment, management, or contact tracing specifically for other STIs (excluding HIV) in the context of one partner having an STI.",yes,"National SOP HIV  PrEP-Nepal -Final _2022-NCASC Nepal.pdf: Page 15, Table 2: 'Hepatitis B screening' at Baseline. Page 18, Table 3: 'Hepatis B antigen screening is recommended at the initiation of PrEP'. Page 23: 'Collect the samples for serum creatinine, Hepatitis B antibody, Hepatitis C antigen'.",ERR: no (REF: yes),Justification not provided,no,Justification not provided,yes,"National SOP HIV  PrEP-Nepal -Final _2022-NCASC Nepal.pdf: Page 15, Table 2: 'syphilis screening' at Baseline, 3 months, 6 months, 9 months, 12 months. Page 18, Table 3: 'Syphilis screening with Rapid Plasma Reagin (RPR) should be part of symptom screening'. Page 23: 'Check the result of RPR- Treat for syphilis'.",ERR: yes (REF: no),"National SOP HIV  PrEP-Nepal -Final _2022-NCASC Nepal.pdf: Page 25, Table 5: 'PrEP does not prevent STIs other than HIV, like syphilis, gonorrhea, chlamydia, trichomonas or chancroid.'",ERR: yes (REF: no),"National SOP HIV  PrEP-Nepal -Final _2022-NCASC Nepal.pdf: Page 25, Table 5: 'PrEP does not prevent STIs other than HIV, like syphilis, gonorrhea, chlamydia, trichomonas or chancroid.'"
NLD,Netherlands,ERR: yes (REF: no),"Netherlands_PrEP_dossier_2017.pdf: Page 39, Table 4.2, 'CSG heeft expertise in het behandelen van de doelgroep en kan de benodigde zorg rond PrEP bieden (exclusief vergoeding van PrEP), is bovendien expert in soa-bestrijding en partnerwaarschuwing...'",yes,"Netherlands_PrEP_dossier_2017.pdf: Page 38, Table 4.1, 'HBV status en vaccinatie' and footnote 5 'Screen volgens landelijk beleid'",yes,"Netherlands_PrEP_dossier_2017.pdf: Page 38, Table 4.1, 'HBV status en vaccinatie' and footnote 5 '...vaccineer indien geindiceerd.'",ERR: no (REF: yes),Justification not provided,yes,"Netherlands_PrEP_dossier_2017.pdf: Page 38, Table 4.1, 'Soa testen: tenminste oraal en rectaal monster plus urine op Chlamydia en Gonnoroe NAAT, syfilis serologie'",yes,"Netherlands_PrEP_dossier_2017.pdf: Page 38, Table 4.1, 'Soa testen: tenminste oraal en rectaal monster plus urine op Chlamydia en Gonnoroe NAAT, syfilis serologie'",yes,"Netherlands_PrEP_dossier_2017.pdf: Page 38, Table 4.1, 'Soa testen: tenminste oraal en rectaal monster plus urine op Chlamydia en Gonnoroe NAAT, syfilis serologie'"
NZL,New Zealand,yes,"ASHM_PrEP_NZ_guidelines_FINAL_Sept2021.pdf: Page 47, 'Partner notification should be undertaken using the most appropriate available resources.' in the 'Testing for STIs' section for PrEP users.",yes,"ASHM_PrEP_NZ_guidelines_FINAL_Sept2021.pdf: Page 23, 'Hepatitis B (if not immune)' as a required investigation for initial Special Authority application. Page 27, 'HBV infection status should be documented by screening serology when PrEP is initiated'. Page 44, Table 7.1, 'Hepatitis B serology (HBsAg, Anti-HBs,Anti-HBc)' listed for baseline and follow-up.",yes,"ASHM_PrEP_NZ_guidelines_FINAL_Sept2021.pdf: Page 23, 'Hepatitis B (if not immune)' listed as a required investigation. Page 27, 'Vaccination against hepatitis A and HBV is recommended for all susceptible priority populations'. Page 44, Table 7.1, 'Vaccinate if non-immune' is noted under 'Hepatitis B serology'.",no,ASHM_PrEP_NZ_guidelines_FINAL_Sept2021.pdf: Not found.,yes,"ASHM_PrEP_NZ_guidelines_FINAL_Sept2021.pdf: Page 12, Box 3.1, point 5, 'Improved access to comprehensive STI vaccination, screening and treatment' and 'quarterly STI screening'. Page 18, 'One or more episodes of rectal gonorrhoea, rectal chlamydia or infectious syphilis, including any STIs diagnosed at screening for PrEP' for eligibility. Page 23, 'Syphilis' as a required investigation. Page 27, 'Clinicians should screen for STIs (specifically gonorrhoea, chlamydia and infectious syphilis)'. Page 44, Table 7.1 and Page 45, Box 7.1, list 'syphilis' for STI screening at baseline and every 3 months.",yes,"ASHM_PrEP_NZ_guidelines_FINAL_Sept2021.pdf: Page 12, Box 3.1, point 5, 'Improved access to comprehensive STI vaccination, screening and treatment' and 'quarterly STI screening'. Page 18, 'One or more episodes of rectal gonorrhoea, rectal chlamydia or infectious syphilis, including any STIs diagnosed at screening for PrEP' for eligibility. Page 27, 'Clinicians should screen for STIs (specifically gonorrhoea, chlamydia and infectious syphilis)'. Page 44, Table 7.1 and Page 45, Box 7.1, list 'gonorrhoea' for STI screening at baseline and every 3 months.",yes,"ASHM_PrEP_NZ_guidelines_FINAL_Sept2021.pdf: Page 12, Box 3.1, point 5, 'Improved access to comprehensive STI vaccination, screening and treatment' and 'quarterly STI screening'. Page 18, 'One or more episodes of rectal gonorrhoea, rectal chlamydia or infectious syphilis, including any STIs diagnosed at screening for PrEP' for eligibility. Page 27, 'Clinicians should screen for STIs (specifically gonorrhoea, chlamydia and infectious syphilis)'. Page 44, Table 7.1 and Page 45, Box 7.1, list 'chlamydia' for STI screening at baseline and every 3 months."
NGA,Nigeria,no,"Nigeria_National Guidelines for HIV Prevention Treatment and Care (2016).pdf: Not explicitly mentioned in the context of STI partner management for PrEP users. While 'serodiscordant couples' are mentioned as a target group for PrEP (page 156), the document does not specify partner testing or treatment for other STIs in this context.",yes,"Nigeria_National Guidelines for HIV Prevention Treatment and Care (2016).pdf: Page 157, 'Administration and Monitoring of PrEP' section: 'Persons eligible for PrEP should be screened for Hepatitis B.'",no,Nigeria_National Guidelines for HIV Prevention Treatment and Care (2016).pdf: Not found in the context of PrEP services/users.,no,Nigeria_National Guidelines for HIV Prevention Treatment and Care (2016).pdf: Not found in the context of PrEP services/users.,yes,"Nigeria_National Guidelines for HIV Prevention Treatment and Care (2016).pdf: Page 159, 'Every 12 months' section: 'Conduct STI testing recommended for sexually active adolescents and adults (i.e., syphilis, gonorrhea, chlamydia)'",yes,"Nigeria_National Guidelines for HIV Prevention Treatment and Care (2016).pdf: Page 159, 'Every 12 months' section: 'Conduct STI testing recommended for sexually active adolescents and adults (i.e., syphilis, gonorrhea, chlamydia)'",yes,"Nigeria_National Guidelines for HIV Prevention Treatment and Care (2016).pdf: Page 159, 'Every 12 months' section: 'Conduct STI testing recommended for sexually active adolescents and adults (i.e., syphilis, gonorrhea, chlamydia)'"
NOR,Norway,no,Justification not provided,no,Justification not provided,no,Justification not provided,no,Justification not provided,ERR: yes (REF: no),"15-774-10 PrEP kunnskapsgrunnlag og anbefaling 120816.no.en.pdf: Page 10, paragraph 1: 'Frequent testing for other soi, such as gonorrhea and syphilis, is recommended as an important offer to PrEP users.'",ERR: yes (REF: no),"15-774-10 PrEP kunnskapsgrunnlag og anbefaling 120816.no.en.pdf: Page 10, paragraph 1: 'Frequent testing for other soi, such as gonorrhea and syphilis, is recommended as an important offer to PrEP users.'",ERR: yes (REF: no),"15-774-10 PrEP kunnskapsgrunnlag og anbefaling 120816.no.en.pdf: Page 9, paragraph 1: 'The main topics related to clinical follow-up and monitoring of people who use PrEP are adherence in use, control for the development of resistance and frequent screening for soi.' 'Soi' is an acronym for sexually transmitted infections. Page 13, paragraph 3: '33% chlamydia' is listed as an STI diagnosed among PrEP users, implying it is part of the 'soi' screening."
PAK,Pakistan,ERR: no (REF: yes),"Pakistan PrEP Guidelines Final 6.24.19 clean.pdf: Not found. The document mentions HIV-related partner testing/status but not STI partner management (e.g., contact tracing, partner treatment for STIs).",yes,"Pakistan PrEP Guidelines Final 6.24.19 clean.pdf: Page 4, paragraph 3: 'hepatitis-B status, with hepatitis B surface antigen testing should be documented prior to PrEP.'; Page 5, Table 1, 'Tests' section for Visit 1 and Page 6, Table 1, 'Tests' section for Visit 4 include 'Hepatitis B surface antigen'.",yes,"Pakistan PrEP Guidelines Final 6.24.19 clean.pdf: Page 7, Table 2, 'Hepatitis B surface antigen - negative' row: 'Offer Hepatitis B virus vaccination'.",no,Justification not provided,ERR: yes (REF: no),"Pakistan PrEP Guidelines Final 6.24.19 clean.pdf: Page 2, 'Eligibility criteria for PrEP' lists 'syphilis' as an STI indicating substantial risk; Page 5, Table 1, 'Screening and PrEP initiation (visit 1)' and subsequent follow-up visits state 'Provide STI testing and treatment, if indicated'.",ERR: yes (REF: no),"Pakistan PrEP Guidelines Final 6.24.19 clean.pdf: Page 2, 'Eligibility criteria for PrEP' lists 'gonorrhoea' as an STI indicating substantial risk; Page 5, Table 1, 'Screening and PrEP initiation (visit 1)' and subsequent follow-up visits state 'Provide STI testing and treatment, if indicated'.",ERR: yes (REF: no),"Pakistan PrEP Guidelines Final 6.24.19 clean.pdf: Page 2, 'Eligibility criteria for PrEP' lists 'chlamydia' as an STI indicating substantial risk; Page 5, Table 1, 'Screening and PrEP initiation (visit 1)' and subsequent follow-up visits state 'Provide STI testing and treatment, if indicated'."
PAN,Panama,no,"Borrador guía PrEP producto 2GR - English.pdf: While serodiscordant couples are mentioned as a target population for PrEP for HIV prevention (Page 10, Page 15), there is no mention of partner testing, treatment, or management services for other STIs.",yes,"Borrador guía PrEP producto 2GR - English.pdf: Page 15, Table No.2, Objective 3, Activities: 'Offer of tests for other sexually transmitted infections (syphilis, hepatitis B and C)'",no,Justification not provided,no,Justification not provided,yes,"Borrador guía PrEP producto 2GR - English.pdf: Page 15, Table No.2, Objective 3, Activities: 'Offer of tests for other sexually transmitted infections (syphilis, hepatitis B and C)'; Page 20: 'syphilis screening could be done at each follow-up visit' (for MSM)",no,"Borrador guía PrEP producto 2GR - English.pdf: While 'other sexually transmitted infections' are mentioned generally, Neisseria gonorrhoeae or gonorrhea is not specifically listed for screening.",no,"Borrador guía PrEP producto 2GR - English.pdf: While 'other sexually transmitted infections' are mentioned generally, Chlamydia trachomatis or Chlamydia is not specifically listed for screening."
PRY,Paraguay,no,Justification not provided,yes,"manual de Profilaxis Pre exposicion del VIH ultimo - English.pdf: Page 13, Table 2, 'Hepatitis B test' specifies 'HBsAg (e.g. rapid test) and anti-HBs research' for initial consultation. Page 16 mentions 'Initial investigation of viral hepatitis B and C is recommended'. Page 19, Table 3, specifies 'HBsAg search (e.g. TR)' for follow-up.",yes,"manual de Profilaxis Pre exposicion del VIH ultimo - English.pdf: Page 8, '2.1 COMBINED PREVENTION', item 8 includes 'Immunizations for HBV, HAV, HPV' as part of the comprehensive prevention package for PrEP users. Page 13, Table 2, under 'EXAMSREQUESTED AT THE FIRST CONSULTATION', mentions 'Evaluate the need for vaccination against...hepatitis B'. Page 16 explicitly states 'Vaccination for HBV is recommended for all people in any age group (three doses of the vaccine). HBV vaccine is indicated regardless of the availability of anti-HBs testing.' in the context of PrEP.",yes,"manual de Profilaxis Pre exposicion del VIH ultimo - English.pdf: Page 8, '2.1 COMBINED PREVENTION', item 8 includes 'Immunizations for HBV, HAV, HPV' as part of the comprehensive prevention package that PrEP is offered within, implying it applies to PrEP users.",yes,"manual de Profilaxis Pre exposicion del VIH ultimo - English.pdf: Page 13, Table 2, specifies 'Syphilis test: rapid test and VDRL' for initial consultation. Page 15, '5.1.5 Testing and treatment of STIs', states 'Rapid test and VDRL test tests...should be performed for syphilis'. Page 19, Table 3, specifies 'VDRL or rapid test' for quarterly follow-up.",yes,"manual de Profilaxis Pre exposicion del VIH ultimo - English.pdf: Page 13, Table 2, under 'Identification of other STIs', explicitly mentions '(chlamydia and gonococcus)' and 'Anal swab, if available' for initial consultation. Page 15, '5.1.5 Testing and treatment of STIs', mentions 'gonococcus studies should be performed'. Page 19, Table 3, specifies 'Identification of other STIs (chlamydia and gonococcus)' and 'Anal or urethral swab (if available)' for quarterly follow-up.",yes,"manual de Profilaxis Pre exposicion del VIH ultimo - English.pdf: Page 13, Table 2, under 'Identification of other STIs', explicitly mentions '(chlamydia and gonococcus)' and 'Anal swab, if available' for initial consultation. Page 15, '5.1.5 Testing and treatment of STIs', mentions 'chlamydia and gonococcus studies should be performed'. Page 19, Table 3, specifies 'Identification of other STIs (chlamydia and gonococcus)' and 'Anal or urethral swab (if available)' for quarterly follow-up."
PHL,Philippines,no,"Prep guidelines 2021 approved philippines.pdf: While 'partner testing' is mentioned (Page 2, V.D), it is in the context of HIV negative results for PrEP referral, not specific STI partner management, treatment, or contact tracing. 'Those who have a sexual partner with one or more HIV risk factors' (Page 2, VI.B.1.f) also refers to HIV risk.",yes,"Prep guidelines 2021 approved philippines.pdf: Page 3, VI.C.2.c: 'HBsAg test done within 30 days prior to PrEP initiation.'",yes,"Prep guidelines 2021 approved philippines.pdf: Page 3, VI.C.2.c.i: 'If the result is negative, recommend hepatitis B vaccination.'",no,Justification not provided,no,"Prep guidelines 2021 approved philippines.pdf: Page 3, VI.C.2.d and Page 4, VI.E.4 mention 'STI screening (syndromic management or etiological diagnosis)' but do not specifically name syphilis or Treponema pallidum as a pathogen to be screened for.",no,"Prep guidelines 2021 approved philippines.pdf: Page 3, VI.C.2.d and Page 4, VI.E.4 mention 'STI screening (syndromic management or etiological diagnosis)' but do not specifically name Neisseria gonorrhoeae or gonorrhea as a pathogen to be screened for.",no,"Prep guidelines 2021 approved philippines.pdf: Page 3, VI.C.2.d and Page 4, VI.E.4 mention 'STI screening (syndromic management or etiological diagnosis)' but do not specifically name Chlamydia trachomatis or Chlamydia as a pathogen to be screened for."
POL,Poland,no,"Poland_Report on the implementation of national HIV program_PART 2_Polish.pdf: The document is a report on the implementation of a national HIV/AIDS program and does not contain clinical guidelines or recommendations for PrEP users or services, including partner management for STIs. PrEP is not mentioned.",ERR: no (REF: yes),"Poland_Report on the implementation of national HIV program_PART 2_Polish.pdf: The document does not mention PrEP services or users, nor does it contain recommendations for HBV or HBsAg screening.",ERR: no (REF: yes),"Poland_Report on the implementation of national HIV program_PART 2_Polish.pdf: The document does not mention PrEP services or users, nor does it contain recommendations for HBV vaccination.",ERR: no (REF: yes),"Poland_Report on the implementation of national HIV program_PART 2_Polish.pdf: The document does not mention PrEP services or users, nor does it contain recommendations for HPV vaccination.",ERR: no (REF: yes),"Poland_Report on the implementation of national HIV program_PART 2_Polish.pdf: The document does not mention PrEP services or users, nor does it contain recommendations for syphilis or Treponema pallidum screening.",ERR: no (REF: yes),"Poland_Report on the implementation of national HIV program_PART 2_Polish.pdf: The document does not mention PrEP services or users, nor does it contain recommendations for Neisseria gonorrhoeae or gonorrhoea screening.",ERR: no (REF: yes),"Poland_Report on the implementation of national HIV program_PART 2_Polish.pdf: The document does not mention PrEP services or users, nor does it contain recommendations for Chlamydia trachomatis or Chlamydia screening."
PRT,Portugal,no,Justification not provided,yes,"Portugal PrEP guideline .pdf: Page 2, point 3j: 'Avaliação do estado serológico para hepatite A, hepatite B, hepatite C e imunização ou tratamento quando indicado;'",yes,"Portugal PrEP guideline .pdf: Page 2, point 3j: 'Avaliação do estado serológico para hepatite A, hepatite B, hepatite C e imunização ou tratamento quando indicado;'",yes,"Portugal PrEP guideline .pdf: Page 2, point 3k: 'Avaliação da indicação de imunização para vírus do papiloma humano (HPV).'",yes,"Portugal PrEP guideline .pdf: Page 9, point F.3: 'O rastreio de IST preconizado deverá incluir sífilis, infeção por Chlamydophila trachomatis e Neisseria gonorrhoeae)'; Page 10, point H.1: 'O rastreio de outras IST deverá incluir sífilis, infeção por N. gonorrheae e C. trachomatis, VHC), incluindo na pessoa assintomática'.",yes,"Portugal PrEP guideline .pdf: Page 9, point F.3: 'O rastreio de IST preconizado deverá incluir sífilis, infeção por Chlamydophila trachomatis e Neisseria gonorrhoeae)'; Page 10, point H.1: 'O rastreio de outras IST deverá incluir sífilis, infeção por N. gonorrheae e C. trachomatis, VHC), incluindo na pessoa assintomática'.",yes,"Portugal PrEP guideline .pdf: Page 9, point F.3: 'O rastreio de IST preconizado deverá incluir sífilis, infeção por Chlamydophila trachomatis e Neisseria gonorrhoeae)'; Page 10, point H.1: 'O rastreio de outras IST deverá incluir sífilis, infeção por N. gonorrheae e C. trachomatis, VHC), incluindo na pessoa assintomática'."
SLE,Sierra Leone,no,Sierre Leone_Consolidated_HIV_Guidelines_.pdf: Not found in the context of PrEP services for a partner having an STI.,yes,"Sierre Leone_Consolidated_HIV_Guidelines_.pdf: Page 55, 'Screening for PrEP eligibility', bullet point: 'Assess for hepatitis B infection'",no,Sierre Leone_Consolidated_HIV_Guidelines_.pdf: Not mentioned in the PrEP section (Section 4.8) of the document.,no,Sierre Leone_Consolidated_HIV_Guidelines_.pdf: Not mentioned in the PrEP section (Section 4.8) of the document.,no,"Sierre Leone_Consolidated_HIV_Guidelines_.pdf: Page 55, 'Follow-up monitoring of clients on PrEP', bullet point: 'Evaluate the patient for any symptoms of STI s at every visit and treat as needed' refers to general STIs, not specific screening for syphilis.",no,"Sierre Leone_Consolidated_HIV_Guidelines_.pdf: Page 55, 'Follow-up monitoring of clients on PrEP', bullet point: 'Evaluate the patient for any symptoms of STI s at every visit and treat as needed' refers to general STIs, not specific screening for Neisseria gonorrhoeae.",no,"Sierre Leone_Consolidated_HIV_Guidelines_.pdf: Page 55, 'Follow-up monitoring of clients on PrEP', bullet point: 'Evaluate the patient for any symptoms of STI s at every visit and treat as needed' refers to general STIs, not specific screening for Chlamydia trachomatis."
SGP,Singapore,no,Justification not provided,yes,"NHIVP PrEP Guidance_2019.pdf: Page 7, section 'a. Hepatitis B virus (HBV) infection'; Page 11, 'Hepatitis B screening' table row",yes,"NHIVP PrEP Guidance_2019.pdf: Page 11, 'Hepatitis B screening' table row; Page 12, 'Other services' table row",yes,"NHIVP PrEP Guidance_2019.pdf: Page 12, 'Other services' table row",yes,"NHIVP PrEP Guidance_2019.pdf: Page 11, 'Syphilis screening' table row; Page 14, 'STI screening and treatment' table row",yes,"NHIVP PrEP Guidance_2019.pdf: Page 12, 'Offer STI screening and treatment' table row; Page 14, 'STI screening and treatment' table row",yes,"NHIVP PrEP Guidance_2019.pdf: Page 12, 'Offer STI screening and treatment' table row; Page 14, 'STI screening and treatment' table row"
SVK,Slovakia,no,"SVK PrEP Guidelines ENG.pdf: The document discusses assessing the PrEP user's sexual partners' HIV status and risky behaviors (e.g., page 7, 'Sexual history' and page 8, 'If a person is in a monogamous relationship, he has HIV serostatus and a state of viral suppression of the partner.'), and mentions 'Partner Services' in literature citation 54 on page 19, but does not explicitly recommend partner(s) testing, treatment, or management for STIs (excluding HIV) in the context of PrEP services.",yes,"SVK PrEP Guidelines ENG.pdf: Page 6, Table 1: 'Ďalšie odporúčané testy na stanovenie rizík PrEP' (Further recommended tests for determining PrEP risks) includes 'Skríning HBV a HCV.' (Screening HBV and HCV). Page 14, section 'Hepatitis B and C infection': 'Hepatitis B infection individuals should be screened for HBV infection before starting PrEP treatment. This includes testing for hepatitis B surface antigen (HBsAg), hepatitis B core antibodies (anti-HBc) and hepatitis B surface antibodies (anti-HBs).'",yes,"SVK PrEP Guidelines ENG.pdf: Page 6, Table 1, footnote §: 'Ak je to možné, očkujte proti hepatitíde B.' (If possible, vaccinate against hepatitis B). Page 14, section 'Hepatitis B and C infection': 'Persons with no signs of prior infection...should be vaccinated against HBV, as individuals who engage in high-risk sexual behavior and drug use are at increased risk of acquiring hepatitis B.'",no,Justification not provided,yes,"SVK PrEP Guidelines ENG.pdf: Page 8, section 'STI screening': 'STI screening should include serological tests for syphilis and nucleic acid amplification tests for gonorrhea and chlamydia from relevant mucous membranes (Table 3).' Page 9, Table 3 explicitly lists 'Syfilis' (Syphilis) screening for various populations (e.g., 'Vek <25 rokov', 'Tehotná') at initiation and follow-up. Page 13, Table 4, footnote ◊: 'STI screening should include serum testing for syphilis and screening for gonorrhea and chlamydia on mucosal sites with potential risk (eg, throat, rectum, genitourinary).'",yes,"SVK PrEP Guidelines ENG.pdf: Page 8, section 'STI screening': 'STI screening should include serological tests for syphilis and nucleic acid amplification tests for gonorrhea and chlamydia from relevant mucous membranes (Table 3).' Page 9, Table 3 explicitly lists 'Genitálna kvapavka' (Genital gonorrhea) screening for various populations at initiation and follow-up. Page 10, Table 3 also lists 'Rektálna kvapavka' and 'Hltanová kvapavka' for men. Page 13, Table 4, footnote ◊: 'STI screening should include serum testing for syphilis and screening for gonorrhea and chlamydia on mucosal sites with potential risk (eg, throat, rectum, genitourinary).'",yes,"SVK PrEP Guidelines ENG.pdf: Page 8, section 'STI screening': 'STI screening should include serological tests for syphilis and nucleic acid amplification tests for gonorrhea and chlamydia from relevant mucous membranes (Table 3).' Page 9, Table 3 explicitly lists 'Genitálne chlamydie' (Genital chlamydia) screening for various populations at initiation and follow-up. Page 10, Table 3 also lists 'Rektálne chlamydie' for men. Page 13, Table 4, footnote ◊: 'STI screening should include serum testing for syphilis and screening for gonorrhea and chlamydia on mucosal sites with potential risk (eg, throat, rectum, genitourinary).'"
ZAF,South Africa,no,"South African Guidelines for Provision of PrEP.pdf: The document mentions 'Voluntary partner HIV testing and treatment' (Page 10, Section 4.3), which is specific to HIV and not other STIs or general partner management for non-HIV STIs.",yes,"South African Guidelines for Provision of PrEP.pdf: Page 12, Table 1, 'Hepatitis B surface antigen (HBsAg)' is listed under 'Baseline Investigations' with 'Action to be taken: If HbsAg+: start PrEP and refer to a doctor for liver function monitoring and management of Hepatitis B infection.'",yes,"South African Guidelines for Provision of PrEP.pdf: Page 12, Table 1, 'Hepatitis B surface antigen (HBsAg)' is listed under 'Baseline Investigations' with 'Action to be taken: If HbsAg: start PrEP and vaccinate, if available'",no,Justification not provided,no,"South African Guidelines for Provision of PrEP.pdf: The document mentions 'Syndromic STI diagnosis and treatment' (Page 10, Section 4.3; Page 12, Table 1) and 'STI screening' (Page 16, Table 4; Page 19, Appendix I; Page 20, Appendix II). However, it does not specify screening for 'syphilis' or 'Treponema pallidum'.",no,"South African Guidelines for Provision of PrEP.pdf: The document mentions 'Syndromic STI diagnosis and treatment' (Page 10, Section 4.3; Page 12, Table 1) and 'STI screening' (Page 16, Table 4; Page 19, Appendix I; Page 20, Appendix II). However, it does not specify screening for 'Neisseria gonorrhoeae' or 'gonorrhoea'.",no,"South African Guidelines for Provision of PrEP.pdf: The document mentions 'Syndromic STI diagnosis and treatment' (Page 10, Section 4.3; Page 12, Table 1) and 'STI screening' (Page 16, Table 4; Page 19, Appendix I; Page 20, Appendix II). However, it does not specify screening for 'Chlamydia trachomatis' or 'Chlamydia'."
SSD,South Sudan,ERR: yes (REF: no),"S. Sudan HIV Consolidated ART Guidelines_10 Sept 2021 2332hrs[6223]RS.pdf: Page 16, 'PrEP should be offered as part of the biomedical component of ‘Combination Prevention’ package that includes... STI prevention and treatment.' Page 23, Section 2.2.5 'STI Management', 'Appropriate sexually transmitted infection treatment, including partner management, should be ensured.'",yes,"S. Sudan HIV Consolidated ART Guidelines_10 Sept 2021 2332hrs[6223]RS.pdf: Page 17, 'PrEP minimum package', includes 'Hepatitis screening'.",no,Justification not provided,no,Justification not provided,no,"S. Sudan HIV Consolidated ART Guidelines_10 Sept 2021 2332hrs[6223]RS.pdf: Page 17, 'PrEP minimum package' lists 'STI screening and diagnosis' generally, but does not mention specific pathogens for PrEP users. Specific syphilis screening is mentioned only for PLHIV (Page 24), which is excluded by instructions.",no,"S. Sudan HIV Consolidated ART Guidelines_10 Sept 2021 2332hrs[6223]RS.pdf: Page 17, 'PrEP minimum package' lists 'STI screening and diagnosis' generally, but does not mention specific pathogens for PrEP users. Specific gonorrhoea mention is tied to HIV diagnosis (Page 24), which is excluded by instructions.",no,"S. Sudan HIV Consolidated ART Guidelines_10 Sept 2021 2332hrs[6223]RS.pdf: Page 17, 'PrEP minimum package' lists 'STI screening and diagnosis' generally, but does not mention specific pathogens for PrEP users. Specific chlamydia mention is tied to HIV diagnosis (Page 24), which is excluded by instructions."
ESP,Spain,no,"Spain_PROFILAXIS_PREEXPOSICION_VIH.es.en.PDF: Not found. The document mentions 'STI treatment' (Page 10, Table 1) and 'STI screening, treatment and management' (Page 11), and identifies 'partners who have STIs' as a risk factor (Page 26), but does not explicitly mention 'partner(s) testing', 'partner(s) treatment', 'partner(s) management', 'partner services', or 'contact tracing' in the context of STIs for PrEP users.",yes,"Spain_PROFILAXIS_PREEXPOSICION_VIH.es.en.PDF: Page 28, section 6.c: 'Hepatitis Serology: ... If you have an acute HBV infection, starting PrEP is contraindicated.' and 'HBV: Vaccination is recommended if serology is negative or antibody levels are below the limit of protection.' This implies HBV screening. Also, Page 33, Table 6, point 1: 'Before starting PrEP, HIV infection, STI screening, hepatitis virus serology, blood and urine tests, and pregnancy tests should be ruled out.'",yes,"Spain_PROFILAXIS_PREEXPOSICION_VIH.es.en.PDF: Page 10, Table 1: 'HAV, HBV and HPV vaccination' under 'Strategies Biomedical'. Page 28, section 6.c: 'HBV: Vaccination is recommended if serology is negative or antibody levels are below the limit of protection.'",yes,"Spain_PROFILAXIS_PREEXPOSICION_VIH.es.en.PDF: Page 10, Table 1: 'HAV, HBV and HPV vaccination' under 'Strategies Biomedical'.",yes,"Spain_PROFILAXIS_PREEXPOSICION_VIH.es.en.PDF: Page 28, section 6.b: 'STI screening: should include gonococcus, chlamydia, syphilis, in all people, even if they are asymptomatic.' Page 29, section 6.1: 'STI screening.' (every 3 months, for follow-up). Page 33, Table 6, point 1: 'Before starting PrEP, ... STI screening... should be ruled out.' and point 2: 'After starting PrEP, an HIV test, STI screening... should be performed every 3 months.'",yes,"Spain_PROFILAXIS_PREEXPOSICION_VIH.es.en.PDF: Page 28, section 6.b: 'STI screening: should include gonococcus, chlamydia, syphilis, in all people, even if they are asymptomatic.' Page 29, section 6.1: 'STI screening.' (every 3 months, for follow-up). Page 33, Table 6, point 1: 'Before starting PrEP, ... STI screening... should be ruled out.' and point 2: 'After starting PrEP, an HIV test, STI screening... should be performed every 3 months.'",yes,"Spain_PROFILAXIS_PREEXPOSICION_VIH.es.en.PDF: Page 28, section 6.b: 'STI screening: should include gonococcus, chlamydia, syphilis, in all people, even if they are asymptomatic.' Page 29, section 6.1: 'STI screening.' (every 3 months, for follow-up). Page 33, Table 6, point 1: 'Before starting PrEP, ... STI screening... should be ruled out.' and point 2: 'After starting PrEP, an HIV test, STI screening... should be performed every 3 months.'"
SWE,Sweden,no,Justification not provided,yes,"Sweden_hiv_prep_2017_v170824.sv.en.pdf: Page 3, 'Before starting treatment', 'Sampling': 'Hepatitis B serology (exclusion of chronic carriers)'",yes,"Sweden_hiv_prep_2017_v170824.sv.en.pdf: Page 3, 'Before starting treatment', 'Vaccination': 'Offer hepatitis B vaccination to anyone who lacks protection'",no,Justification not provided,yes,"Sweden_hiv_prep_2017_v170824.sv.en.pdf: Page 3, 'Before starting treatment', 'Sampling': 'syphilis serology'; Page 3, 'Follow-up', 'Thereafter every 3 months': 'Sampling for chlamydia, gonorrhea, syphilis'",yes,"Sweden_hiv_prep_2017_v170824.sv.en.pdf: Page 3, 'Before starting treatment', 'Sampling': 'gonorrhea from all premises'; Page 3, 'Follow-up', 'Thereafter every 3 months': 'Sampling for chlamydia, gonorrhea, syphilis'",yes,"Sweden_hiv_prep_2017_v170824.sv.en.pdf: Page 3, 'Before starting treatment', 'Sampling': 'Chlamydia and gonorrhea from all premises'; Page 3, 'Follow-up', 'Thereafter every 3 months': 'Sampling for chlamydia, gonorrhea, syphilis'"
CHE,Switzerland,no,Justification not provided,yes,"fcsh-recommendations-prep-hiv (1).pdf: Page 2, 'Before PrEP is prescribed' section: 'Exclusion of hepatitis B infection based on HBsAg and ALT'; 'Additional laboratory investigations: serology tests for hepatitis A, B and C'",yes,"fcsh-recommendations-prep-hiv (1).pdf: Page 2, 'Before PrEP is prescribed' section: 'Hepatitis A and B vaccination if the patient is not immune'",no,Justification not provided,yes,"fcsh-recommendations-prep-hiv (1).pdf: Page 2, 'Before PrEP is prescribed' section: 'Additional laboratory investigations: serology tests for... syphilis'; Page 2, 'Every 3 months' section: 'Syphilis serology'",yes,"fcsh-recommendations-prep-hiv (1).pdf: Page 2, 'Before PrEP is prescribed' section: 'Anal, oral and urethral (vaginal) smears for C. trachomatis and N. gonorrhoeae'; Page 2, 'Every 3 months' section: 'Anal, oral and urethral (vaginal) smears for C. trachomatis and N. gonorrhoeae'",yes,"fcsh-recommendations-prep-hiv (1).pdf: Page 2, 'Before PrEP is prescribed' section: 'Anal, oral and urethral (vaginal) smears for C. trachomatis and N. gonorrhoeae'; Page 2, 'Every 3 months' section: 'Anal, oral and urethral (vaginal) smears for C. trachomatis and N. gonorrhoeae'"
TJK,Republic of Tajikistan,no,Justification not provided,yes,"TJK PrEP Guidelines ENG.pdf: Page 14, section 3.7: 'It is also recommended to test individuals receiving PrEP for hepatitis B virus surface antigen (HBsAg).'; Page 18, section IV: 'serological testing for HIV and viral hepatitis B and C.'",yes,"TJK PrEP Guidelines ENG.pdf: Page 14, section 3.7: 'In cases where HBsAg is not detected and there is no information about vaccination in the past, clients are advised to vaccination against hepatitis B'",no,Justification not provided,ERR: yes (REF: no),"TJK PrEP Guidelines ENG.pdf: Page 7, section I: 'PrEP should be included in the package of services for prevention, which includes screening for STIs and their treatment...' and 'PrEP does not protect against syphilis...'",ERR: yes (REF: no),"TJK PrEP Guidelines ENG.pdf: Page 7, section I: 'PrEP should be included in the package of services for prevention, which includes screening for STIs and their treatment...' and 'PrEP does not protect against... gonorrhea...'",ERR: yes (REF: no),"TJK PrEP Guidelines ENG.pdf: Page 7, section I: 'PrEP should be included in the package of services for prevention, which includes screening for STIs and their treatment...' and 'PrEP does not protect against... chlamydia...'"
THA,Thailand,ERR: no (REF: yes),"thailand_national_guidelines_for_pre-exposure_prophylaxis_prep_2021_chapters_1-2.pdf: Partner management is mentioned for HIV discordant couples, but not specifically for other STIs (excluding HIV) in the context of PrEP services in the provided text.",yes,"thailand_national_guidelines_for_pre-exposure_prophylaxis_prep_2021_chapters_1-2.pdf: Page 13, Table 1.1 'Laboratory examination' mentions 'hepatitis B at Month 0'; 'Minimum laboratory examination' mentions 'Monitoring of hepatitis B (HBsAg)'.",ERR: no (REF: yes),"thailand_national_guidelines_for_pre-exposure_prophylaxis_prep_2021_chapters_1-2.pdf: The document mentions 'vaccination recommended for Hepatitis C' (Page 13, Table 1.1) but does not explicitly recommend vaccination for Hepatitis B.",ERR: no (REF: yes),Justification not provided,yes,"thailand_national_guidelines_for_pre-exposure_prophylaxis_prep_2021_chapters_1-2.pdf: Page 13, Table 1.1 'Laboratory examination' mentions 'Syphilis ... at Month 0, every 3-6 months'.",yes,"thailand_national_guidelines_for_pre-exposure_prophylaxis_prep_2021_chapters_1-2.pdf: Page 13, Table 1.1 'Laboratory examination' mentions 'gonorrhea ... at Month 0, every 3-6 months'.",yes,"thailand_national_guidelines_for_pre-exposure_prophylaxis_prep_2021_chapters_1-2.pdf: Page 13, Table 1.1 'Laboratory examination' mentions 'chlamydia ... at Month 0, every 3-6 months'."
GBR,United Kingdom,no,"2018-PrEP-Guidelines.pdf: The document mentions intimate partner/domestic violence in the context of sexual health autonomy (Page 52, Table 5.1.1), but not partner management specifically related to STI diagnosis or treatment for a sexual partner of a person diagnosed with an STI (excluding HIV). No explicit mention of contact tracing or partner services for STIs was found.",yes,"2018-PrEP-Guidelines.pdf: Page 12, Recommendation 24: 'We recommend that baseline screening for hepatitis B should be undertaken in those of unknown hepatitis B status to exclude active hepatitis B infection... (1A).'; Page 79, Table 7.5.1: 'Hepatitis B (+ vaccination if non-immune)' is listed for baseline and every subsequent 3 months.",yes,"2018-PrEP-Guidelines.pdf: Page 12, Recommendation 24: '...vaccination initiated in those who are non-immune. (1A).'; Page 67, Section 6.4.6: 'HBV vaccination should be offered as per current guidelines'.",no,Justification not provided,yes,"2018-PrEP-Guidelines.pdf: Page 12, Recommendation 28: 'We recommend a full STI screen at baseline including syphilis serology... (1A).'; Page 13, Recommendation 40: 'We recommend 3-monthly screening for bacterial STIs (chlamydia, gonorrhoea and syphilis)... (1B).'; Page 79, Table 7.5.1: 'STI screen' is listed for baseline and every subsequent 3 months, with '3-monthly' frequency.",yes,"2018-PrEP-Guidelines.pdf: Page 12, Recommendation 28: '...NAAT testing for gonococcal and chlamydial infection at sites of exposure (genital, rectal, pharyngeal). (1A).'; Page 13, Recommendation 40: 'We recommend 3-monthly screening for bacterial STIs (chlamydia, gonorrhoea and syphilis)... (1B).'; Page 79, Table 7.5.1: 'STI screen' is listed for baseline and every subsequent 3 months, with '3-monthly' frequency.",yes,"2018-PrEP-Guidelines.pdf: Page 12, Recommendation 28: '...NAAT testing for gonococcal and chlamydial infection at sites of exposure (genital, rectal, pharyngeal). (1A).'; Page 13, Recommendation 40: 'We recommend 3-monthly screening for bacterial STIs (chlamydia, gonorrhoea and syphilis)... (1B).'; Page 79, Table 7.5.1: 'STI screen' is listed for baseline and every subsequent 3 months, with '3-monthly' frequency."
USA,United States,yes,"PrEPguideline2021_PublicCommentDraft.pdf: Page 32, Section: LABORATORY TESTS FOR PATIENTS BEING CONSIDERED FOR ORAL PREP, last paragraph: 'Heterosexually-active men and women being evaluated for, or being prescribed PrEP, in whom gonorrhea or chlamydia infection is detected, should be offered expedited partner therapy (EPT)... Patients with syphilis or HIV diagnosed should be referred for partner services.'",yes,"PrEPguideline2021_PublicCommentDraft.pdf: Page 33, Section: TESTING FOR INFECTION WITH HEPATITIS B VIRUS (HBV): 'Ideally, prior to prescribing PrEP, patients should be screened for HBV...'; Page 43, Table 5: 'Hep B serology: Screening/Baseline Visit (X)'",yes,"PrEPguideline2021_PublicCommentDraft.pdf: Page 34, first paragraph: 'Patients who are not immune and do not have HBV infection should be vaccinated.'; Page 62, Table 8: 'Hepatitis B vaccine (Yes)'",yes,"PrEPguideline2021_PublicCommentDraft.pdf: Page 62, Table 8: 'HPV vaccine (Through age 26)'",yes,"PrEPguideline2021_PublicCommentDraft.pdf: Page 16, Table 1a: 'Bacterial STI screening for MSM and transgender women who have sex with men... Bacterial STI screening for all sexually-active patients...'; Footnote 2 on Page 17 specifies 'syphilis'; Page 31, Section: TESTING FOR SEXUALLY TRANSMITTED INFECTIONS: 'Tests to screen for syphilis are recommended for all adults prescribed PrEP, both at screening and at semi-annual visits.'; Page 43, Table 5: 'Syphilis: Screening/Baseline Visit (X), Q 3 months (X for MSM /TGW), Q 6 months (X), When stopping PrEP (X for MSM/TGW)'",yes,"PrEPguideline2021_PublicCommentDraft.pdf: Page 16, Table 1a: 'Bacterial STI screening for MSM and transgender women who have sex with men... Bacterial STI screening for all sexually-active patients...'; Footnote 2 on Page 17 specifies 'Gonorrhea'; Page 31, Section: TESTING FOR SEXUALLY TRANSMITTED INFECTIONS: 'Tests to screen for gonorrhea are recommended for all sexually active adults prescribed PrEP, both at screening, for MSM at quarterly visits, and for women at semi-annual visits.'; Page 43, Table 5: 'Gonorrhea: Screening/Baseline Visit (X), Q 3 months (X for MSM /TGW), Q 6 months (X), When stopping PrEP (X for MSM/TGW)'",yes,"PrEPguideline2021_PublicCommentDraft.pdf: Page 16, Table 1a: 'Bacterial STI screening for MSM and transgender women who have sex with men... Bacterial STI screening for all sexually-active patients... Chlamydia screening for women - vaginal'; Footnote 2 on Page 17 specifies 'chlamydia'; Page 31, Section: TESTING FOR SEXUALLY TRANSMITTED INFECTIONS: 'Tests to screen for chlamydia are recommended for all sexually active MSM prescribed PrEP, both at screening prior to initiation and at quarterly visits.' and 'screening for chlamydia is recommended at initiation and every 12 months for all sexually active women as a component of PrEP care.'; Page 43, Table 5: 'Chlamydia: Screening/Baseline Visit (X), Q 3 months (X for MSM /TGW), Q 6 months (X), Q 12 months (X for women), When stopping PrEP (X for MSM/TGW)'"
UGA,Uganda,no,"consolidated_guidelines_hiv_prevention_uganda.pdf: The document discusses partner management in the context of HIV status disclosure and testing for HIV-discordant couples (e.g., Page 37, Table 12; Page 40, Table 14), and general risk reduction (Page 30, Table 8). However, it does not explicitly mention partner(s) testing, treatment, or management for STIs (excluding HIV) specifically for PrEP users.",yes,"consolidated_guidelines_hiv_prevention_uganda.pdf: Page 30, Table 8, 'Screening for PrEP eligibility' section states: 'Assess for hepatitis B infection: if negative, patient is eligible for PrEP; if positive, refer patient for management'.",no,"consolidated_guidelines_hiv_prevention_uganda.pdf: While HBV vaccination is generally recommended for all people in endemic areas (Page 67, Section 6.5.5), the document does not specifically state it as a recommendation at the initiation or follow-up of PrEP services/use (e.g., in Table 8, which details the PrEP process).",no,"consolidated_guidelines_hiv_prevention_uganda.pdf: HPV vaccination is recommended for young girls and adolescents in general (Page 70, Figure 9; Page 77, Section 6.8.3), but this recommendation is not specifically tied to the initiation or follow-up of PrEP services/use.",no,"consolidated_guidelines_hiv_prevention_uganda.pdf: Page 30, Table 8, 'Follow-up/monitoring clients on PrEP' mentions 'Evaluate the patient for any symptoms of STIs at every visit and treat as needed'. However, it does not specifically mention screening for 'syphilis' or 'Treponema pallidum' by name in the context of PrEP services.",no,"consolidated_guidelines_hiv_prevention_uganda.pdf: Page 30, Table 8, 'Follow-up/monitoring clients on PrEP' mentions 'Evaluate the patient for any symptoms of STIs at every visit and treat as needed'. However, it does not specifically mention screening for 'Neisseria gonorrhoeae' or 'gonorrhoea' by name in the context of PrEP services.",no,"consolidated_guidelines_hiv_prevention_uganda.pdf: Page 30, Table 8, 'Follow-up/monitoring clients on PrEP' mentions 'Evaluate the patient for any symptoms of STIs at every visit and treat as needed'. However, it does not specifically mention screening for 'Chlamydia trachomatis' or 'Chlamydia' by name in the context of PrEP services."
UKR,Ukraine,ERR: yes (REF: no),"UKR HIV Guidelines - Annex 4 ENG.pdf: Page 2, Counselling people before prescribing PrEP, point h: 'assessment of the risk of intimate partner violence'",yes,"UKR HIV Guidelines - Annex 4 ENG.pdf: Page 1, List of examinations before prescribing PrEP Mandatory: 'HBV screening: HBsAg**'",yes,"UKR HIV Guidelines - Annex 4 ENG.pdf: Page 1, List of examinations before prescribing PrEP Mandatory: 'In the absence of HBV markers, vaccination is offered.'",no,Justification not provided,ERR: no (REF: yes),Justification not provided,no,Justification not provided,no,Justification not provided
URY,Uruguay,no,Justification not provided,yes,"Guia_PreProfilaxis_VIH_Uruguay_2020.pdf: Page 12, Table 8, 'Hepatitis B' specifies 'HBsAg, HBsAc, HbcAc' as screening methods.",yes,"Guia_PreProfilaxis_VIH_Uruguay_2020.pdf: Page 9, Table 5, 'Indicación de vacunación de VHB, VHA, VPH según corresponda.'; Page 11, Table 7, 'Chequeo de cumplimiento de indicación de vacunación: VHB, VPH, VHA según corresponda.'",yes,"Guia_PreProfilaxis_VIH_Uruguay_2020.pdf: Page 9, Table 5, 'Indicación de vacunación de VHB, VHA, VPH según corresponda.'; Page 11, Table 7, 'Chequeo de cumplimiento de indicación de vacunación: VHB, VPH, VHA según corresponda.'",yes,"Guia_PreProfilaxis_VIH_Uruguay_2020.pdf: Page 3, 'PrEP e infecciones de transmisión sexual (ITS)' states: 'Tanto en la consulta inicial, como en el seguimiento, se debe realizar testeo y tratamiento de sífilis, Chlamydia y gonorrea.'; Page 12, Table 8, 'Sífilis' specifies 'Test rápido. Con antecedentes de sífilis: VDRL/RPR' as screening methods.",yes,"Guia_PreProfilaxis_VIH_Uruguay_2020.pdf: Page 3, 'PrEP e infecciones de transmisión sexual (ITS)' states: 'Tanto en la consulta inicial, como en el seguimiento, se debe realizar testeo y tratamiento de sífilis, Chlamydia y gonorrea.'; Page 12, Table 8, 'Chlamydia y gonococo' specifies screening methods including 'gonococo'.",yes,"Guia_PreProfilaxis_VIH_Uruguay_2020.pdf: Page 3, 'PrEP e infecciones de transmisión sexual (ITS)' states: 'Tanto en la consulta inicial, como en el seguimiento, se debe realizar testeo y tratamiento de sífilis, Chlamydia y gonorrea.'; Page 12, Table 8, 'Chlamydia y gonococo' specifies screening methods including 'Chlamydia'."
UZB,Uzbekistan,no,"UZB PrEP Guidelines ENG.pdf: No mention of partner(s) testing, treatment, management, services, or contact tracing for STIs (excluding HIV) in the context of one partner having an STI.",yes,"UZB PrEP Guidelines ENG.pdf: Page 4, last paragraph: 'Therefore, before starting PrEP, it is necessary to determine the serological status of HBV'; Page 6, table 'Recommended clinical and laboratory tests before PrEP', row 'Hepatitis B testing': 'A study on HBsAg is necessary.'; Page 7, table 'Recommended examinations during prEP', row 'Serological studies for hepatitis B and C, syphilis': 'Every 6 months.'",yes,"UZB PrEP Guidelines ENG.pdf: Page 6, table 'Recommended clinical and laboratory tests before PrEP', row 'Hepatitis B testing': 'Deciding whether to vaccinate against Hepatitis B in the absence of antibodies to HBsAg'",no,Justification not provided,yes,"UZB PrEP Guidelines ENG.pdf: Page 6, table 'Recommended clinical and laboratory tests before PrEP', row 'STI test': 'serological examination for syphilis.'; Page 7, table 'Recommended examinations during prEP', row 'Serological studies for hepatitis B and C, syphilis': 'Every 6 months'",no,Justification not provided,no,Justification not provided
VNM,Vietnam,no,Justification not provided,yes,"Vietnam National Guidelines for HIV 2017 _EN.pdf: Page 42, Section 10.2, Step 5: 'Perform creatinine test and HbsAg test'",ERR: no (REF: yes),Vietnam National Guidelines for HIV 2017 _EN.pdf: Not mentioned for PrEP users; only for PEP or general HIV-infected populations.,no,Vietnam National Guidelines for HIV 2017 _EN.pdf: Not mentioned for PrEP users; only for general HIV-infected women.,ERR: no (REF: yes),"Vietnam National Guidelines for HIV 2017 _EN.pdf: Page 43, Table 14 mentions 'sexually transmitted infections' screening for PrEP users, but does not specify syphilis.",ERR: no (REF: yes),"Vietnam National Guidelines for HIV 2017 _EN.pdf: Page 43, Table 14 mentions 'sexually transmitted infections' screening for PrEP users, but does not specify Neisseria gonorrhoeae or gonorrhoea.",ERR: no (REF: yes),"Vietnam National Guidelines for HIV 2017 _EN.pdf: Page 43, Table 14 mentions 'sexually transmitted infections' screening for PrEP users, but does not specify Chlamydia trachomatis or Chlamydia."
ZMB,Zambia,no,"NASF 2017 - 2021.pdf: The PrEP section (Page 44) and the STI section (Page 36-37) do not explicitly mention partner testing, treatment, management, services, or contact tracing specifically for STIs (excluding HIV) in the context of PrEP users.",ERR: no (REF: yes),NASF 2017 - 2021.pdf: The document discusses Viral Hepatitis generally (Page 50) and PrEP separately (Page 44). There is no explicit recommendation for HBV or HBsAg screening at initiation or follow-up for PrEP users.,no,NASF 2017 - 2021.pdf: The document discusses Viral Hepatitis generally (Page 50) and PrEP separately (Page 44). There is no explicit recommendation for Hepatitis B vaccination at initiation of PrEP services/use.,no,NASF 2017 - 2021.pdf: The document does not mention Human Papillomavirus (HPV) vaccination in relation to PrEP services/use.,ERR: no (REF: yes),"NASF 2017 - 2021.pdf: The PrEP section (Page 44) mentions integration with sexual and reproductive health services. The STI section (Page 36-37) discusses general STI screening, but there is no explicit recommendation to screen for syphilis or Treponema pallidum at initiation or follow-up of PrEP services/use.",no,"NASF 2017 - 2021.pdf: The PrEP section (Page 44) mentions integration with sexual and reproductive health services. The STI section (Page 36-37) discusses general STI screening, but there is no explicit recommendation to screen for Neisseria gonorrhoeae (NG) or gonorrhoea at initiation or follow-up of PrEP services/use.",no,"NASF 2017 - 2021.pdf: The PrEP section (Page 44) mentions integration with sexual and reproductive health services. The STI section (Page 36-37) discusses general STI screening, but there is no explicit recommendation to screen for Chlamydia trachomatis (CT) or Chlamydia at initiation or follow-up of PrEP services/use."
ZWE,Zimbabwe,no,"Implementation plan for HIV PrEP in Zimbabwe 2018-2020.pdf: The document discusses sero-discordant couples in the context of HIV prevention (Page 8, 9, 17) but does not mention partner testing, treatment, or management specifically for other STIs when one partner has an STI.",yes,"Implementation plan for HIV PrEP in Zimbabwe 2018-2020.pdf: Page 27, Table 5: 'Hepatitis B surface antigen (HBsAg) - At baseline, if available. Rationale: To identify undiagnosed current hepatitis B (HBV) infection.'",yes,"Implementation plan for HIV PrEP in Zimbabwe 2018-2020.pdf: Page 27, Table 5: 'Hepatitis B surface antigen (HBsAg) - Rationale: If negative, consider vaccination against hepatitis B.'",no,Implementation plan for HIV PrEP in Zimbabwe 2018-2020.pdf: Not found.,yes,"Implementation plan for HIV PrEP in Zimbabwe 2018-2020.pdf: Page 27, Table 5: 'Rapid Syphilis Test - At baseline if available. Rationale: To diagnose and treat syphilis infection.'",no,"Implementation plan for HIV PrEP in Zimbabwe 2018-2020.pdf: Not found. The document mentions general 'STI testing' and 'Syndromic STI management' (Page 47, 48) but does not specify screening for Neisseria gonorrhoeae (NG) or gonorrhoea by pathogen.",no,"Implementation plan for HIV PrEP in Zimbabwe 2018-2020.pdf: Not found. The document mentions general 'STI testing' and 'Syndromic STI management' (Page 47, 48) but does not specify screening for Chlamydia trachomatis (CT) or Chlamydia by pathogen."
